#BEGIN_DRUGCARD DB02212

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
33018

# Chemical_Formula:
H2O7P2

# Chemical_IUPAC_Name:
hydrogen (hydrogen phosphonatooxy)phosphonate

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Pyrophosphate 2-

# HET_ID:
POP

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/H4O7P2/c1-8(2,3)7-9(4,5)6/h(H2,1,2,3)(H2,4,5,6)/p-2

# InChI_Key:
InChIKey=XPPKVPWEQAFLFU-UHFFFAOYSA-L

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
2212

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
175.9592

# Molecular_Weight_Mono:
175.927575442

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1B99

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
0

# Predicted_LogS:
0

# Predicted_Water_Solubility:
Not Available

# Primary_Accession_No:
DB02212

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
4995

# PubChem_Substance_ID:
46508771

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT02631

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
O[P@]([O-])(=O)O[P@@](O)([O-])=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:20:54 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_10_Cellular_Location:
Not Available

# Drug_Target_10_Chromosome_Location:
Not Available

# Drug_Target_10_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_10_Essentiality:
Non-Essential

# Drug_Target_10_GenAtlas_ID:
Not Available

# Drug_Target_10_GenBank_ID_Gene:
AF071051

# Drug_Target_10_GenBank_ID_Protein:
3420295

# Drug_Target_10_GeneCard_ID:
Not Available

# Drug_Target_10_Gene_Name:
bls

# Drug_Target_10_Gene_Sequence:
>1542 bp
ATGGGGGCACCGGTTCTTCCGGCTGCCTTCGGGTTCCTGGCCTCCGCCCGAACGGGCGGG
GGCCGGGCCCCCGGCCCGGTCTTCGCGACCCGGGGCAGCCACACCGACATCGACACGCCC
CAGGGGGAGCGCTCGCTCGCGGCGACCCTGGTGCACGCCCCCTCGGTCGCGCCCGACCGC
GCGGTGGCGCGCTCCCTCACCGGCGCGCCCACCACCGCGGTGCTCGCCGGTGAGATCTAC
AACCGGGACGAACTCCTCTCCGTGCTGCCCGCCGGACCCGCGCCGGAGGGGGACGCGGAG
CTGGTCCTGCGGCTGCTGGAACGCTATGACCTGCATGCCTTCCGGCTGGTGAACGGGCGC
TTCGCGACCGTGGTGCGGACCGGGGACCGGGTCCTGCTCGCCACCGACCACGCCGGTTCG
GTGCCGCTGTACACCTGTGTGGCGCCGGGCGAGGTCCGGGCGTCCACCGAGGCCAAGGCG
CTCGCCGCGCACCGCGACCCGAAGGGCTTCCCGCTCGCGGACGCCCGCCGGGTCGCCGGT
CTGACCGGTGTCTACCAGGTGCCCGCGGGCGCCGTGATGGACATCGACCTCGGCTCGGGC
ACCGCCGTCACCCACCGCACCTGGACCCCGGGCCTCTCCCGCCGCATCCTGCCGGAGGGC
GAGGCCGTCGCGGCCGTGCGGGCCGCGCTGGAGAAGGCCGTCGCCCAGCGGGTCACCCCC
GGCGACACCCCGTTGGTGGTGCTCTCCGGCGGAATCGACTCCTCCGGGGTCGCGGCCTGT
GCGCACCGGGCGGCCGGGGAACTGGACACGGTGTCCATGGGCACCGACACGTCCAACGAG
TTCCGCGAGGCCCGGGCGGTCGTCGACCATCTGCGCACCCGGCACCGGGAGATCACCATC
CCGACCACCGAGCTGCTGGCGCAGCTCCCGTACGCGGTGTGGGCCTCCGAGTCGGTGGAC
CCGGACATCATCGAGTACCTGCTCCCCCTGACAGCGCTCTACCGGGCGCTCGACGGGCCG
GAGCGCCGCATCCTCACCGGGTACGGCGCGGACATCCCCCTCGGGGGCATGCACCGCGAG
GACCGGCTGCCCGCGCTGGACACCGTTCTCGCGCACGACATGGCCACCTTCGACGGGCTG
AACGAGATGTCCCCGGTGCTGTCCACGCTGGCGGGGCACTGGACCACCCACCCGTACTGG
GACCGGGAGGTCCTCGATCTGCTGGTCTCGCTGGAGGCCGGGCTCAAGCGGCGGCACGGC
CGGGACAAGTGGGTGCTGCGCGCCGCGATGGCCGACGCCCTCCCGGCGGAGACCGTCAAC
CGGCCCAAGCTGGGCGTCCACGAGGGCTCGGGCACCACGTCCTCGTTCTCCCGGCTGCTG
CTGGACCACGGTGTCGCCGAGGACCGCGTCCACGAGGCGAAGCGGCAGGTGGTGCGCGAG
CTGTTCGATCTCACGGTCGGGGGCGGACGGCACCCCTCCGAGGTGGACACCGACGATGTG
GTGCGCTCCGTGGCCGACCGGACCGCGCGGGGGGCGGCCTAG

# Drug_Target_10_General_Function:
Amino acid transport and metabolism

# Drug_Target_10_General_References:
10681345	Jensen SE, Elder KJ, Aidoo KA, Paradkar AS: Enzymes catalyzing the early steps of clavulanic acid biosynthesis are encoded by two sets of paralogous genes in Streptomyces clavuligerus. Antimicrob Agents Chemother. 2000 Mar;44(3):720-6.
9689037	Bachmann BO, Li R, Townsend CA: beta-Lactam synthetase: a new biosynthetic enzyme. Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9082-6.

# Drug_Target_10_HGNC_ID:
Not Available

# Drug_Target_10_HPRD_ID:
Not Available

# Drug_Target_10_ID:
2885

# Drug_Target_10_Locus:
Not Available

# Drug_Target_10_Molecular_Weight:
54530

# Drug_Target_10_Name:
Carboxyethyl-arginine beta-lactam-synthase

# Drug_Target_10_Number_of_Residues:
513

# Drug_Target_10_PDB_ID:
1MC1

# Drug_Target_10_Pathway:
Not Available

# Drug_Target_10_Pfam_Domain_Function:
PF00733	Asn_synthase

# Drug_Target_10_Protein_Sequence:
>Carboxyethyl-arginine beta-lactam-synthase
MGAPVLPAAFGFLASARTGGGRAPGPVFATRGSHTDIDTPQGERSLAATLVHAPSVAPDR
AVARSLTGAPTTAVLAGEIYNRDELLSVLPAGPAPEGDAELVLRLLERYDLHAFRLVNGR
FATVVRTGDRVLLATDHAGSVPLYTCVAPGEVRASTEAKALAAHRDPKGFPLADARRVAG
LTGVYQVPAGAVMDIDLGSGTAVTHRTWTPGLSRRILPEGEAVAAVRAALEKAVAQRVTP
GDTPLVVLSGGIDSSGVAACAHRAAGELDTVSMGTDTSNEFREARAVVDHLRTRHREITI
PTTELLAQLPYAVWASESVDPDIIEYLLPLTALYRALDGPERRILTGYGADIPLGGMHRE
DRLPALDTVLAHDMATFDGLNEMSPVLSTLAGHWTTHPYWDREVLDLLVSLEAGLKRRHG
RDKWVLRAAMADALPAETVNRPKLGVHEGSGTTSSFSRLLLDHGVAEDRVHEAKRQVVRE
LFDLTVGGGRHPSEVDTDDVVRSVADRTARGAA

# Drug_Target_10_Reaction:
ATP + L-N2-(2-carboxyethyl)arginine = AMP + diphosphate + deoxyamidinoproclavaminate

# Drug_Target_10_Signals:
None

# Drug_Target_10_Specific_Function:
ATP + L-2-N-(2-carboxyethyl)arginine = AMP + diphosphate + deoxyamidinoproclavaminate

# Drug_Target_10_SwissProt_ID:
Q9R8E3

# Drug_Target_10_SwissProt_Name:
BLS_STRCL

# Drug_Target_10_Synonyms:
Beta-lactam synthetase
EC 6.3.3.4

# Drug_Target_10_Theoretical_pI:
6.33

# Drug_Target_10_Transmembrane_Regions:
None

# Drug_Target_11_Cellular_Location:
Cytoplasm (By similarity)

# Drug_Target_11_Chromosome_Location:
1

# Drug_Target_11_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_11_Essentiality:
Non-Essential

# Drug_Target_11_GenAtlas_ID:
Not Available

# Drug_Target_11_GenBank_ID_Gene:
U30255

# Drug_Target_11_GenBank_ID_Protein:
984325

# Drug_Target_11_GeneCard_ID:
PGD

# Drug_Target_11_Gene_Name:
PGD

# Drug_Target_11_Gene_Sequence:
>1452 bp
ATGGCCCAAGCTGACATCGCGCTGATCGGATTGGCCGTCATGGGCCAGAACTTAATTCTG
AACATGAATGACCACGGCTTTGTGGTCTGTGCTTTTAATAGGACTGTCTCCAAAGTTGAC
GATTTCTTGGCCAATGAGGCAAAGGGAACCAAAGTGGTGGGTGCCCAGTCCCTGAAAGAG
ATGGTCTCCAAGCTGAAGAAGCCCCGGCGGATCATCCTCCTGGTGAAGGCTGGGCAAGCT
GTGGATGATTTCATCGAGAAATTGGTACCATTGTTGGATACTGGTGACATCATCATTGAC
GGAGGAAATTCTGAATATAGGGACACCACAAGACGGTGCCGAGACCTCAAAGGCAAGGGA
ATTTTATTTGTGGGGAGCGGAGTCAGTGGTGGAGAGGAAGGGCCCCGGTATGGCCCATCG
CTCATGCCAGGAGGGAACAAAGAAGCGTGGCCCCACATCAAGACCATCTTCCAAGGCATT
GCTGCAAAAGTGGGAACTGGAGAACCCTGCTGTGACTGGGTGGGAGATGAGGGAGCAGGC
CACTTTGTGAAGATGGTGCACAACGGGATAGAGTATGGGGACATGCAGCTGATCTGTGAG
GCATACCACCTGATGAAAGACGTGCTGGGCATGGCGCAGGACGAGATGGCCCAGGCCTTT
GAGGATTGGAATAAGACAGAGCTAGACTCATTCCTGATTGAAATCACAGCCAATATTCTC
AAGTTCCAAGACACCGATGGCAAACACCTGCTGCCAAAGATCAGGGACAGCGCGGGGCAG
AAGGGCACAGGGAAGTGGACCGCCATCTCCGCCCTGGAATACGGCGTACCCGTCACCCTC
ATTGGAGAAGCTGTCTTTGCTCGGTGCTTATCATCTCTGAAGGATGAGAGAATTCAAGCT
AGCAAAAAGCTGAAGGGTCCCCAGAAGTTCCAGTTTGATGGTGATAAGAAATCATTCCTG
GAGGACATTCGGAAGGCACTCTACGCTTCCAAGATCATCTCTTACGCTCAAGGCTTTATG
CTGCTAAGGCAGGCAGCCACCGAGTTTGGCTGGACTCTCAATTATGGTGGCATCGCCCTG
ATGTGGAGAGGGGGCTGCATCATTAGAAGTGTATTCCTAGGAAAGATAAAGGATGCATTT
GATCGAAACCCGGAACTTCAGAACCTCCTACTGGACGACTTCTTTAAGTCAGCTGTTGAA
AACTGCCAGGACTCCTGGCGGCGGGCAGTCAGCACTGGGGTCCAGGCTGGCATTCCCATG
CCCTGTTTTACCACTGCCCTCTCCTTCTATGACGGGTACAGACATGAGATGCTTCCAGCC
AGCCTCATCCAGGCTCAGCGGGATTACTTCGGGGCTCACACCTATGAACTCTTGGCCAAA
CCAGGGCAGTTTATCCACACCAACTGGACAGGCCATGGTGGCACCGTGTCATCCTCGTCA
TACAATGCCTGA

# Drug_Target_11_General_Function:
Carbohydrate transport and metabolism

# Drug_Target_11_General_References:
15489334	Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.
8978909	Tsui SK, Chan JY, Waye MM, Fung KP, Lee CY: Identification of a cDNA encoding 6-phosphogluconate dehydrogenase from a human heart cDNA library. Biochem Genet. 1996 Oct;34(9-10):367-73.

# Drug_Target_11_HGNC_ID:
GNC:8891

# Drug_Target_11_HPRD_ID:
Not Available

# Drug_Target_11_ID:
6040

# Drug_Target_11_Locus:
1p36.3-p36.13

# Drug_Target_11_Molecular_Weight:
53139.6

# Drug_Target_11_Name:
6-phosphogluconate dehydrogenase, decarboxylating

# Drug_Target_11_Number_of_Residues:
483

# Drug_Target_11_PDB_ID:
2PGD

# Drug_Target_11_Pathway:
Not Available

# Drug_Target_11_Pfam_Domain_Function:
PF00393	6PGD
PF03446	NAD_binding_2

# Drug_Target_11_Protein_Sequence:
>6-phosphogluconate dehydrogenase, decarboxylating
MAQADIALIGLAVMGQNLILNMNDHGFVVCAFNRTVSKVDDFLANEAKGTKVVGAQSLKE
MVSKLKKPRRIILLVKAGQAVDDFIEKLVPLLDTGDIIIDGGNSEYRDTTRRCRDLKAKG
ILFVGSGVSGGEEGARYGPSLMPGGNKEAWPHIKTIFQGIAAKVGTGEPCCDWVGDEGAG
HFVKMVHNGIEYGDMQLICEAYHLMKDVLGMAQDEMAQAFEDWNKTELDSFLIEITANIL
KFQDTDGKHLLPKIRDSAGQKGTGKWTAISALEYGVPVTLIGEAVFARCLSSLKDERIQA
SKKLKGPQKFQFDGDKKSFLEDIRKALYASKIISYAQGFMLLRQAATEFGWTLNYGGIAL
MWRGGCIIRSVFLGKIKDAFDRNPELQNLLLDDFFKSAVENCQDSWRRAVSTGVQAGIPM
PCFTTALSFYDGYRHEMLPASLIQAQRDYFGAHTYELLAKPGQFIHTNWTGHGGTVSSSS
YNA

# Drug_Target_11_Reaction:
Not Available

# Drug_Target_11_Signals:
None

# Drug_Target_11_Specific_Function:
6-phospho-D-gluconate + NADP(+) = D-ribulose 5-phosphate + CO(2) + NADPH

# Drug_Target_11_SwissProt_ID:
P52209

# Drug_Target_11_SwissProt_Name:
6PGD_HUMAN

# Drug_Target_11_Synonyms:
Not Available

# Drug_Target_11_Theoretical_pI:
7.25

# Drug_Target_11_Transmembrane_Regions:
None

# Drug_Target_12_Cellular_Location:
Cytoplasm

# Drug_Target_12_Chromosome_Location:
Not Available

# Drug_Target_12_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_12_Essentiality:
Non-Essential

# Drug_Target_12_GenAtlas_ID:
Not Available

# Drug_Target_12_GenBank_ID_Gene:
U14003

# Drug_Target_12_GenBank_ID_Protein:
537068

# Drug_Target_12_GeneCard_ID:
Not Available

# Drug_Target_12_Gene_Name:
ppa

# Drug_Target_12_Gene_Sequence:
>531 bp
ATGAGCTTACTCAACGTCCCTGCGGGTAAAGATCTGCCGGAAGACATCTACGTTGTTATT
GAGATCCCGGCTAACGCAGATCCGATCAAATACGAAATCGACAAAGAGAGCGGCGCACTG
TTCGTTGACCGCTTCATGTCCACCGCGATGTTCTATCCATGCAACTACGGTTACATCAAC
CACACCCTGTCTCTGGACGGTGACCCGGTTGACGTACTGGTCCCAACTCCGTACCCGCTG
CAGCCGGGTTCTGTGATCCGTTGCCGTCCGGTTGGCGTTCTGAAAATGACCGACGAAGCC
GGTGAAGATGCGAAACTGGTTGCGGTTCCGCACAGCAAGCTGAGCAAAGAATACGATCAC
ATTAAAGACGTTAACGATCTGCCTGAACTGCTGAAAGCGCAAATCGCTCACTTCTTCGAG
CACTACAAAGACCTCGAAAAAGGCAAGTGGGTGAAAGTTGAAGGTTGGGAAAACGCAGAA
GCCGCTAAAGCTGAAATCGTTGCCTCCTTCGAGCGCGCAAAGAATAAATAA

# Drug_Target_12_General_Function:
Energy production and conversion

# Drug_Target_12_General_References:
1645654	Lahti R, Salminen T, Latonen S, Heikinheimo P, Pohjanoksa K, Heinonen J: Genetic engineering of Escherichia coli inorganic pyrophosphatase. Tyr55 and Tyr141 are important for the structural integrity. Eur J Biochem. 1991 Jun 1;198(2):293-7.
1974462	Lahti R, Pohjanoksa K, Pitkaranta T, Heikinheimo P, Salminen T, Meyer P, Heinonen J: A site-directed mutagenesis study on Escherichia coli inorganic pyrophosphatase. Glutamic acid-98 and lysine-104 are important for structural integrity, whereas aspartic acids-97 and -102 are essential for catalytic activity. Biochemistry. 1990 Jun 19;29(24):5761-6.
2160278	Lahti R, Kolakowski LF Jr, Heinonen J, Vihinen M, Pohjanoksa K, Cooperman BS: Conservation of functional residues between yeast and E. coli inorganic pyrophosphatases. Biochim Biophys Acta. 1990 May 8;1038(3):338-45.
2848015	Lahti R, Pitkaranta T, Valve E, Ilta I, Kukko-Kalske E, Heinonen J: Cloning and characterization of the gene encoding inorganic pyrophosphatase of Escherichia coli K-12. J Bacteriol. 1988 Dec;170(12):5901-7.
7610040	Burland V, Plunkett G 3rd, Sofia HJ, Daniels DL, Blattner FR: Analysis of the Escherichia coli genome VI: DNA sequence of the region from 92.8 through 100 minutes. Nucleic Acids Res. 1995 Jun 25;23(12):2105-19.
7971944	Kankare J, Neal GS, Salminen T, Glumoff T, Glumhoff T [corrected to Glumoff T, Cooperman BS, Lahti R, Goldman A: The structure of E.coli soluble inorganic pyrophosphatase at 2.7 A resolution. Protein Eng. 1994 Jul;7(7):823-30.
8383066	Kaneko S, Ichiba T, Hirano N, Hachimori A: Modification of tryptophan 149 of inorganic pyrophosphatase from Escherichia coli. Int J Biochem. 1993 Feb;25(2):233-8.
8664256	Kankare J, Salminen T, Lahti R, Cooperman BS, Baykov AA, Goldman A: Crystallographic identification of metal-binding sites in Escherichia coli inorganic pyrophosphatase. Biochemistry. 1996 Apr 16;35(15):4670-7.
9201917	Harutyunyan EH, Oganessyan VY, Oganessyan NN, Avaeva SM, Nazarova TI, Vorobyeva NN, Kurilova SA, Huber R, Mather T: Crystal structure of holo inorganic pyrophosphatase from Escherichia coli at 1.9 A resolution. Mechanism of hydrolysis. Biochemistry. 1997 Jun 24;36(25):7754-60.
9237692	Avaeva S, Kurilova S, Nazarova T, Rodina E, Vorobyeva N, Sklyankina V, Grigorjeva O, Harutyunyan E, Oganessyan V, Wilson K, Dauter Z, Huber R, Mather T: Crystal structure of Escherichia coli inorganic pyrophosphatase complexed with SO4(2-). Ligand-induced molecular asymmetry. FEBS Lett. 1997 Jun 30;410(2-3):502-8.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.
9298646	Link AJ, Robison K, Church GM: Comparing the predicted and observed properties of proteins encoded in the genome of Escherichia coli K-12. Electrophoresis. 1997 Aug;18(8):1259-313.

# Drug_Target_12_HGNC_ID:
Not Available

# Drug_Target_12_HPRD_ID:
Not Available

# Drug_Target_12_ID:
2757

# Drug_Target_12_Locus:
Not Available

# Drug_Target_12_Molecular_Weight:
19704

# Drug_Target_12_Name:
Inorganic pyrophosphatase

# Drug_Target_12_Number_of_Residues:
176

# Drug_Target_12_PDB_ID:
2EIP

# Drug_Target_12_Pathway:
Not Available

# Drug_Target_12_Pfam_Domain_Function:
PF00719	Pyrophosphatase

# Drug_Target_12_Protein_Sequence:
>Inorganic pyrophosphatase
MSLLNVPAGKDLPEDIYVVIEIPANADPIKYEIDKESGALFVDRFMSTAMFYPCNYGYIN
HTLSLDGDPVDVLVPTPYPLQPGSVIRCRPVGVLKMTDEAGEDAKLVAVPHSKLSKEYDH
IKDVNDLPELLKAQIAHFFEHYKDLEKGKWVKVEGWENAEAAKAEIVASFERAKNK

# Drug_Target_12_Reaction:
diphosphate + H2O = 2 phosphate

# Drug_Target_12_Signals:
None

# Drug_Target_12_Specific_Function:
Diphosphate + H(2)O = 2 phosphate

# Drug_Target_12_SwissProt_ID:
P0A7A9

# Drug_Target_12_SwissProt_Name:
IPYR_ECOLI

# Drug_Target_12_Synonyms:
EC 3.6.1.1
PPase
Pyrophosphate phospho- hydrolase

# Drug_Target_12_Theoretical_pI:
4.80

# Drug_Target_12_Transmembrane_Regions:
None

# Drug_Target_13_Cellular_Location:
Cytoplasm. Nucleus

# Drug_Target_13_Chromosome_Location:
Not Available

# Drug_Target_13_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_13_Essentiality:
Non-Essential

# Drug_Target_13_GenAtlas_ID:
NME1

# Drug_Target_13_GenBank_ID_Gene:
X75598

# Drug_Target_13_GenBank_ID_Protein:
Not Available

# Drug_Target_13_GeneCard_ID:
Not Available

# Drug_Target_13_Gene_Name:
NME1

# Drug_Target_13_Gene_Sequence:
>459 bp
ATGGCCAACTGTGAGCGTACCTTCATTGCGATCAAACCAGATGGGGTCCAGCGGGGTCTT
GTGGGAGAGATTATCAAGCGTTTTGAGCAGAAAGGATTCCGCCTTGTTGGTCTGAAATTC
ATGCAAGCTTCCGAAGATCTTCTCAAGGAACACTACGTTGACCTGAAGGACCGTCCATTC
TTTGCCGGCCTGGTGAAATACATGCACTCAGGGCCGGTAGTTGCCATGGTCTGGGAGGGG
CTGAATGTGGTGAAGACGGGCCGAGTCATGCTCGGGGAGACCAACCCTGCAGACTCCAAG
CCTGGGACCATCCGTGGAGACTTCTGCATACAAGTTGGCAGGAACATTATACATGGCAGT
GATTCTGTGGAGAGTGCAGAGAAGGAGATCGGCTTGTGGTTTCACCCTGAGGAACTGGTA
GATTACACGAGCTGTGCTCAGAACTGGATCTATGAATGA

# Drug_Target_13_General_Function:
Involved in nucleoside diphosphate kinase activity

# Drug_Target_13_General_References:
10512675	Manda R, Kohno T, Matsuno Y, Takenoshita S, Kuwano H, Yokota J: Identification of genes (SPON2 and C20orf2) differentially expressed between cancerous and noncancerous lung cells by mRNA differential display. Genomics. 1999 Oct 1;61(1):5-14.
11835509	Min K, Song HK, Chang C, Kim SY, Lee KJ, Suh SW: Crystal structure of human nucleoside diphosphate kinase A, a metastasis suppressor. Proteins. 2002 Feb 15;46(3):340-2.
12628186	Fan Z, Beresford PJ, Oh DY, Zhang D, Lieberman J: Tumor suppressor NM23-H1 is a granzyme A-activated DNase during CTL-mediated apoptosis, and the nucleosome assembly protein SET is its inhibitor. Cell. 2003 Mar 7;112(5):659-72.
12972261	Chen Y, Gallois-Montbrun S, Schneider B, Veron M, Morera S, Deville-Bonne D, Janin J: Nucleotide binding to nucleoside diphosphate kinases: X-ray structure of human NDPK-A in complex with ADP and comparison to protein kinases. J Mol Biol. 2003 Sep 26;332(4):915-26.
1851158	Gilles AM, Presecan E, Vonica A, Lascu I: Nucleoside diphosphate kinase from human erythrocytes. Structural characterization of the two polypeptide chains responsible for heterogeneity of the hexameric enzyme. J Biol Chem. 1991 May 15;266(14):8784-9.
2056128	Hailat N, Keim DR, Melhem RF, Zhu XX, Eckerskorn C, Brodeur GM, Reynolds CP, Seeger RC, Lottspeich F, Strahler JR, et al.: High levels of p19/nm23 protein in neuroblastoma are associated with advanced stage disease and with N-myc gene amplification. J Clin Invest. 1991 Jul;88(1):341-5.
2509941	Rosengard AM, Krutzsch HC, Shearn A, Biggs JR, Barker E, Margulies IM, King CR, Liotta LA, Steeg PS: Reduced Nm23/Awd protein in tumour metastasis and aberrant Drosophila development. Nature. 1989 Nov 9;342(6246):177-80.
7916650	Wang L, Patel U, Ghosh L, Chen HC, Banerjee S: Mutation in the nm23 gene is associated with metastasis in colorectal cancer. Cancer Res. 1993 Feb 15;53(4):717-20.
8270257	Dooley S, Seib T, Engel M, Theisinger B, Janz H, Piontek K, Zang KD, Welter C: Isolation and characterization of the human genomic locus coding for the putative metastasis control gene nm23-H1. Hum Genet. 1994 Jan;93(1):63-6.

# Drug_Target_13_HGNC_ID:
HGNC:7849

# Drug_Target_13_HPRD_ID:
Not Available

# Drug_Target_13_ID:
5294

# Drug_Target_13_Locus:
17q21.3

# Drug_Target_13_Molecular_Weight:
17149

# Drug_Target_13_Name:
Nucleoside diphosphate kinase A

# Drug_Target_13_Number_of_Residues:
152

# Drug_Target_13_PDB_ID:
1JXV

# Drug_Target_13_Pathway:
Adefovir Dipivoxil Pathway	SMP00418
Gemcitabine Pathway	SMP00446
Methotrexate Pathway	SMP00432
Tenofovir Pathway	SMP00419

# Drug_Target_13_Pfam_Domain_Function:
PF00334	NDK

# Drug_Target_13_Protein_Sequence:
>Nucleoside diphosphate kinase A
MANCERTFIAIKPDGVQRGLVGEIIKRFEQKGFRLVGLKFMQASEDLLKEHYVDLKDRPF
FAGLVKYMHSGPVVAMVWEGLNVVKTGRVMLGETNPADSKPGTIRGDFCIQVGRNIIHGS
DSVESAEKEIGLWFHPEELVDYTSCAQNWIYE

# Drug_Target_13_Reaction:
Not Available

# Drug_Target_13_Signals:
None

# Drug_Target_13_Specific_Function:
Major role in the synthesis of nucleoside triphosphates other than ATP

# Drug_Target_13_SwissProt_ID:
P15531

# Drug_Target_13_SwissProt_Name:
NDKA_HUMAN

# Drug_Target_13_Synonyms:
EC 2.7.4.6
GAAD
Granzyme A-activated DNase
Metastasis inhibition factor nm23
NDK A
NDP kinase A
Tumor metastatic process-associated protein
nm23-H1

# Drug_Target_13_Theoretical_pI:
6.11

# Drug_Target_13_Transmembrane_Regions:
None

# Drug_Target_14_Cellular_Location:
Cytoplasmic

# Drug_Target_14_Chromosome_Location:
Not Available

# Drug_Target_14_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_14_Essentiality:
Non-Essential

# Drug_Target_14_GenAtlas_ID:
Not Available

# Drug_Target_14_GenBank_ID_Gene:
M17461

# Drug_Target_14_GenBank_ID_Protein:
215481

# Drug_Target_14_GeneCard_ID:
Not Available

# Drug_Target_14_Gene_Name:
P2

# Drug_Target_14_Gene_Sequence:
>1998 bp
ATGCCGAGGAGAGCTCCCGCGTTCCCTCTGAGCGATATCAAGGCTCAGATGCTGTTCGCA
AATAACATCAAGGCCCAACAAGCCTCGAAGCGTAGCTTCAAAGAGGGGGCGATTGAAACG
TACGAAGGGCTGCTTTCAGTAGACCCTCGGTTTTTGAGTTTCAAGAACGAGCTCTCTCGG
TATCTGACCGACCACTTCCCGGCGAACGTCGACGAGTATGGTCGTGTTTATGGAAACGGT
GTTCGTACCAACTTCTTTGGTATGCGCCACATGAACGGGTTTCCAATGATCCCCGCGACG
TGGCCACTCGCTTCCAACCTTAAGAAACGTGCCGACGCTGACCTAGCCGATGGCCCTGTT
TCTGAGCGCGACAATCTACTCTTTCGCGCCGCAGTCCGGCTTATGTTTTCAGATCTAGAG
CCTGTTCCGCTGAAGATCCGTAAAGGATCGTCAACCTGCATCCCGTATTTTTCTAACGAT
ATGGGAACGAAGATCGAGATCGCCGAGCGCGCTCTTGAGAAAGCGGAAGAAGCTGGCAAT
CTGATGCTGCAAGGTAAGTTTGATGACGCCTACCAGCTCCACCAAATGGGTGGTGCCTAT
TACGTCGTGTATCGTGCACAATCGACCGATGCTATCACACTCGACCCTAAGACCGGAAAA
TTCGTGTCAAAGGATCGTATGGTCGCTGACTTCGAATACGCAGTCACGGGCGGTGAGCAA
GGCTCGCTGTTCGCTGCTTCGAAGGATGCCTCTCGTTTGAAGGAACAGTACGGGATAGAT
GTCCCGGACGGGTTTTTCTGCGAGCGGCGTCGTACCGCTATGGGTGGTCCGTTCGCGTTG
AACGCTCCTATCATGGCCGTTGCGCAACCTGTGCGAAACAAAATTTACTCCAAGTACGCT
TACACCTTTCACCATACTACTCGTCTTAATAAGGAGGAAAAGGTGAAAGAGTGGTCGTTG
TGCGTCGCTACTGACGTATCCGACCACGACACGTTCTGGCCTGGATGGCTGCGGGATCTC
ATCTGTGATGAACTGCTCAACATGGGGTACGCTCCGTGGTGGGTTAAGTTGTTCGAGACC
TCGCTCAAACTGCCCGTTTACGTGGGCGCTCCTGCTCCTGAGCAGGGCCACACGTTGTTG
GGTGATCCGTCCAACCCTGATCTCGAAGTTGGTCTCTCGTCCGGACAAGGGGCGACCGAC
CTCATGGGCACGTTGCTCATGAGTATCACCTACCTGGTGATGCAACTTGATCACACCGCT
CCTCACCTCAACAGTCGAATCAAGGACATGCCATCAGCATGCCGCTTTCTTGACTCGTAT
TGGCAAGGACACGAGGAGATCCGTCAGATCTCAAAATCTGATGATGCTATACTTGGCTGG
ACCAAAGGTCGTGCTTTGGTTGGTGGTCATCGTTTGTTCGAGATGCTGAAAGAGGGTAAG
GTTAACCCCTCACCTTACATGAAGATCTCCTACGAGCACGGTGGCGCCTTCCTTGGTGAC
ATCCTGCTTTACGACTCGCGTCGTGAGCCTGGCTCTGCCATCTTCGTTGGTAACATCAAC
TCAATGCTGAACAACCAGTTCAGCCCTGAGTACGGTGTCCAATCGGGCGTTCGCGACCGA
TCTAAGCGCAAACGGCCGTTCCCCGGTCTTGCTTGGGCGTCGATGAAAGATACCTACGGT
GCCTGTCCGATCTACTCTGATGTGCTGGAGGCGATCGAGCGTTGCTGGTGGAACGCGTTC
GGTGAGTCGTACCGTGCGTATCGTGAAGATATGCTTAAACGCGACACTCTCGAACTATCA
CGCTACGTTGCGTCGATGGCTCGTCAAGCCGGGCTGGCTGAACTCACTCCCATTGATTTG
GAGGTGCTTGCTGACCCGAACAAACTCCAGTATAAGTGGACCGAGGCCGATGTCTCGGCG
AATATCCACGAGGTACTGATGCATGGCGTATCGGTCGAAAAGACTGAGCGCTTTCTCCGT
TCTGTAATGCCGAGGTAA

# Drug_Target_14_General_Function:
Involved in RNA binding

# Drug_Target_14_General_References:
3346944	Mindich L, Nemhauser I, Gottlieb P, Romantschuk M, Carton J, Frucht S, Strassman J, Bamford DH, Kalkkinen N: Nucleotide sequence of the large double-stranded RNA segment of bacteriophage phi 6: genes specifying the viral replicase and transcriptase. J Virol. 1988 Apr;62(4):1180-5.

# Drug_Target_14_HGNC_ID:
Not Available

# Drug_Target_14_HPRD_ID:
Not Available

# Drug_Target_14_ID:
2647

# Drug_Target_14_Locus:
Not Available

# Drug_Target_14_Molecular_Weight:
74923

# Drug_Target_14_Name:
RNA-directed RNA polymerase

# Drug_Target_14_Number_of_Residues:
665

# Drug_Target_14_PDB_ID:
1UVN

# Drug_Target_14_Pathway:
Not Available

# Drug_Target_14_Pfam_Domain_Function:
PF00680	RdRP_1

# Drug_Target_14_Protein_Sequence:
>RNA-directed RNA polymerase
MPRRAPAFPLSDIKAQMLFANNIKAQQASKRSFKEGAIETYEGLLSVDPRFLSFKNELSR
YLTDHFPANVDEYGRVYGNGVRTNFFGMRHMNGFPMIPATWPLASNLKKRADADLADGPV
SERDNLLFRAAVRLMFSDLEPVPLKIRKGSSTCIPYFSNDMGTKIEIAERALEKAEEAGN
LMLQGKFDDAYQLHQMGGAYYVVYRAQSTDAITLDPKTGKFVSKDRMVADFEYAVTGGEQ
GSLFAASKDASRLKEQYGIDVPDGFFCERRRTAMGGPFALNAPIMAVAQPVRNKIYSKYA
YTFHHTTRLNKEEKVKEWSLCVATDVSDHDTFWPGWLRDLICDELLNMGYAPWWVKLFET
SLKLPVYVGAPAPEQGHTLLGDPSNPDLEVGLSSGQGATDLMGTLLMSITYLVMQLDHTA
PHLNSRIKDMPSACRFLDSYWQGHEEIRQISKSDDAILGWTKGRALVGGHRLFEMLKEGK
VNPSPYMKISYEHGGAFLGDILLYDSRREPGSAIFVGNINSMLNNQFSPEYGVQSGVRDR
SKRKRPFPGLAWASMKDTYGACPIYSDVLEAIERCWWNAFGESYRAYREDMLKRDTLELS
RYVASMARQAGLAELTPIDLEVLADPNKLQYKWTEADVSANIHEVLMHGVSVEKTERFLR
SVMPR

# Drug_Target_14_Reaction:
nucleoside triphosphate + RNAn = diphosphate + RNAn+1

# Drug_Target_14_Signals:
None

# Drug_Target_14_Specific_Function:
Nucleoside triphosphate + RNA(n) = diphosphate + RNA(n+1)

# Drug_Target_14_SwissProt_ID:
P11124

# Drug_Target_14_SwissProt_Name:
RDRP_BPPH6

# Drug_Target_14_Synonyms:
EC 2.7.7.48
Protein P2

# Drug_Target_14_Theoretical_pI:
7.03

# Drug_Target_14_Transmembrane_Regions:
None

# Drug_Target_15_Cellular_Location:
Cytoplasm

# Drug_Target_15_Chromosome_Location:
Not Available

# Drug_Target_15_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_15_Essentiality:
Non-Essential

# Drug_Target_15_GenAtlas_ID:
Not Available

# Drug_Target_15_GenBank_ID_Gene:
AE005674

# Drug_Target_15_GenBank_ID_Protein:
24053342

# Drug_Target_15_GeneCard_ID:
Not Available

# Drug_Target_15_Gene_Name:
metK

# Drug_Target_15_Gene_Sequence:
>1167 bp
GTGATATTAAATATGGCAAAACACCTTTTTACGTCCGAGTCCGTCTCTGAAGGGCATCCT
GACAAAATTGCTGACCAAATCTCTGATGCCGTTTTAGACGCGATCCTCGAACAGGATCCG
AAAGCACGCGTTGCTTGCGAAACCTACGTAAAAACCGGCATGGTTTTAGTTGGCGGCGAA
ATCACCACCAGCGCCTGGGTAGACATCGAAGAGATCACCCGTAACACCGTTCGCGAAATT
GGCTATGTGCATTCCGACATGGGCTTTGACGCTAACTCCTGTGCGGTTCTGAGCGCTATC
GGCAAACAGTCTCCTGACATCAACCAAGGCGTTGACCGTGCCGATCCGCTGGAACAGGGC
GCGGGTGACCAGGGTCTGATGTTTGGCTACGCAACTAATGAAACCGACGTGCTGATGCCA
GCACCTATCACCTATGCACACCGTCTGGTACAGCGTCAGGCTGAAGTGCGTAAAAACGGC
ACTCTGCCGTGGCTGCGCCCGGACGCGAAAAGCCAGGTGACTTTCCAGTATGACGACGGC
AAAATCGTTGGTATTGATGCTGTCGTGCTTTCCACTCAGCACTCTGAAGAGATCGACCAG
AAATCGCTGCAAGAAGCGGTAATGGAAGAGATCATCAAGCCAATTCTGCCCGCTGAATGG
CTGACTTCTGCCACCAAATTCTTCATCAACCCGACCGGTCGTTTCGTTATCGGTGGCCCA
ATGGGTGACTGCGGTCTGACTGGCCGTAAAATTATCGTTGATACCTACGGCGGCATGGCG
CGTCACGGTGGCGGTGCATTCTCTGGTAAAGATCCATCAAAAGTGGACCGTTCCGCAGCC
TACGCAGCACGTTATGTCGCGAAAAACATCGTTGCTGCTGGCCTGGCCGATCGTTGTGAA
ATTCAGGTTTCCTACGCAATCGGCGTGGCTGAACCGACCTCCATCATGGTAGAAACTTTC
GGTACTGAGAAAGTGCCTTCTGAACAACTGACTCTGCTGGTACGTGAGTTCTTCGACCTG
CGCCCATACGGACTGATTCAGATGCTGGATCTGCTGCACCCGATCTACAAAGAAACCGCA
GCATACGGTCACTTTGGTCGTGAACATTTCCCGTGGGAAAAAACCGACAAAGCGCAGCTG
CTGCGCGATGCTGCCGGTCTGAAGTAA

# Drug_Target_15_General_Function:
Coenzyme transport and metabolism

# Drug_Target_15_General_References:
12384590	Jin Q, Yuan Z, Xu J, Wang Y, Shen Y, Lu W, Wang J, Liu H, Yang J, Yang F, Zhang X, Zhang J, Yang G, Wu H, Qu D, Dong J, Sun L, Xue Y, Zhao A, Gao Y, Zhu J, Kan B, Ding K, Chen S, Cheng H, Yao Z, He B, Chen R, Ma D, Qiang B, Wen Y, Hou Y, Yu J: Genome sequence of Shigella flexneri 2a: insights into pathogenicity through comparison with genomes of Escherichia coli K12 and O157. Nucleic Acids Res. 2002 Oct 15;30(20):4432-41.
12704152	Wei J, Goldberg MB, Burland V, Venkatesan MM, Deng W, Fournier G, Mayhew GF, Plunkett G 3rd, Rose DJ, Darling A, Mau B, Perna NT, Payne SM, Runyen-Janecky LJ, Zhou S, Schwartz DC, Blattner FR: Complete genome sequence and comparative genomics of Shigella flexneri serotype 2a strain 2457T. Infect Immun. 2003 May;71(5):2775-86.

# Drug_Target_15_HGNC_ID:
Not Available

# Drug_Target_15_HPRD_ID:
Not Available

# Drug_Target_15_ID:
2727

# Drug_Target_15_Locus:
Not Available

# Drug_Target_15_Molecular_Weight:
41952

# Drug_Target_15_Name:
S-adenosylmethionine synthetase

# Drug_Target_15_Number_of_Residues:
384

# Drug_Target_15_PDB_ID:
1RG9

# Drug_Target_15_Pathway:
Not Available

# Drug_Target_15_Pfam_Domain_Function:
PF00438	S-AdoMet_synt_N
PF02772	S-AdoMet_synt_M
PF02773	S-AdoMet_synt_C

# Drug_Target_15_Protein_Sequence:
>S-adenosylmethionine synthetase
MAKHLFTSESVSEGHPDKIADQISDAVLDAILEQDPKARVACETYVKTGMVLVGGEITTS
AWVDIEEITRNTVREIGYVHSDMGFDANSCAVLSAIGKQSPDINQGVDRADPLEQGAGDQ
GLMFGYATNETDVLMPAPITYAHRLVQRQAEVRKNGTLPWLRPDAKSQVTFQYDDGKIVG
IDAVVLSTQHSEEIDQKSLQEAVMEEIIKPILPAEWLTSATKFFINPTGRFVIGGPMGDC
GLTGRKIIVDTYGGMARHGGGAFSGKDPSKVDRSAAYAARYVAKNIVAAGLADRCEIQVS
YAIGVAEPTSIMVETFGTEKVPSEQLTLLVREFFDLRPYGLIQMLDLLHPIYKETAAYGH
FGREHFPWEKTDKAQLLRDAAGLK

# Drug_Target_15_Reaction:
ATP + L-methionine + H2O = phosphate + diphosphate + S-adenosyl-L-methionine

# Drug_Target_15_Signals:
None

# Drug_Target_15_Specific_Function:
Catalyzes the formation of S-adenosylmethionine from methionine and ATP. The overall synthetic reaction is composed of two sequential steps, AdoMet formation and the subsequent tripolyphosphate hydrolysis which occurs prior to release of AdoMet from the enzyme

# Drug_Target_15_SwissProt_ID:
P0A820

# Drug_Target_15_SwissProt_Name:
METK_SHIFL

# Drug_Target_15_Synonyms:
AdoMet synthetase
EC 2.5.1.6
MAT
Methionine adenosyltransferase

# Drug_Target_15_Theoretical_pI:
4.89

# Drug_Target_15_Transmembrane_Regions:
None

# Drug_Target_16_Cellular_Location:
Not Available

# Drug_Target_16_Chromosome_Location:
Not Available

# Drug_Target_16_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_16_Essentiality:
Non-Essential

# Drug_Target_16_GenAtlas_ID:
Not Available

# Drug_Target_16_GenBank_ID_Gene:
X73124

# Drug_Target_16_GenBank_ID_Protein:
Not Available

# Drug_Target_16_GeneCard_ID:
Not Available

# Drug_Target_16_Gene_Name:
thiE

# Drug_Target_16_Gene_Sequence:
>669 bp
ATGACTCGTATTTCTCGGGAAATGATGAAAGAGTTATTATCTGTATACTTCATTATGGGG
TCAAACAATACGAAAGCCGATCCTGTTACAGTTGTACAAAAAGCGTTAAAAGGCGGTGCC
ACCCTGTACCAGTTCCGTGAAAAAGGCGGGGATGCGCTGACAGGAGAGGCTCGGATTAAA
TTTGCTGAAAAAGCGCAGGCAGCTTGCCGTGAAGCTGGTGTTCCGTTCATTGTCAATGAT
GATGTGGAATTGGCTCTGAATCTGAAAGCTGATGGTATCCACATCGGCCAGGAAGACGCA
AATGCGAAAGAGGTAAGAGCTGCCATAGGTGATATGATTCTCGGCGTTTCTGCCCATACG
ATGTCTGAGGTGAAGCAAGCCGAAGAAGACGGAGCGGATTATGTCGGGCTTGGGCCGATC
TATCCGACTGAAACGAAAAAAGATACGAGAGCGGTACAGGGTGTATCTCTTATCGAAGCA
GTGCGCCGCCAAGGCATCAGCATTCCAATTGTCGGCATCGGCGGAATCACAATAGATAAT
GCCGCACCTGTTATCCAAGCGGGGGCCGATGGCGTCAGTATGATCAGCGCCATCAGTCAG
GCGGAGGATCCTGAGAGTGCTGCACGCAAGTTTCGTGAGGAAATTCAAACGTATAAAACA
GGAAGATAA

# Drug_Target_16_General_Function:
Coenzyme transport and metabolism

# Drug_Target_16_General_References:
10350464	Chiu HJ, Reddick JJ, Begley TP, Ealick SE: Crystal structure of thiamin phosphate synthase from Bacillus subtilis at 1.25 A resolution. Biochemistry. 1999 May 18;38(20):6460-70.
7934828	Glaser P, Kunst F, Arnaud M, Coudart MP, Gonzales W, Hullo MF, Ionescu M, Lubochinsky B, Marcelino L, Moszer I, et al.: Bacillus subtilis genome project: cloning and sequencing of the 97 kb region from 325 degrees to 333 degrees. Mol Microbiol. 1993 Oct;10(2):371-84.
9139923	Zhang Y, Taylor SV, Chiu HJ, Begley TP: Characterization of the Bacillus subtilis thiC operon involved in thiamine biosynthesis. J Bacteriol. 1997 May;179(9):3030-5.
9384377	Kunst F, Ogasawara N, Moszer I, Albertini AM, Alloni G, Azevedo V, Bertero MG, Bessieres P, Bolotin A, Borchert S, Borriss R, Boursier L, Brans A, Braun M, Brignell SC, Bron S, Brouillet S, Bruschi CV, Caldwell B, Capuano V, Carter NM, Choi SK, Codani JJ, Connerton IF, Danchin A, et al.: The complete genome sequence of the gram-positive bacterium Bacillus subtilis. Nature. 1997 Nov 20;390(6657):249-56.

# Drug_Target_16_HGNC_ID:
Not Available

# Drug_Target_16_HPRD_ID:
Not Available

# Drug_Target_16_ID:
2428

# Drug_Target_16_Locus:
Not Available

# Drug_Target_16_Molecular_Weight:
23681

# Drug_Target_16_Name:
Thiamine-phosphate pyrophosphorylase

# Drug_Target_16_Number_of_Residues:
222

# Drug_Target_16_PDB_ID:
1G4T

# Drug_Target_16_Pathway:
Not Available

# Drug_Target_16_Pfam_Domain_Function:
PF02581	TMP-TENI

# Drug_Target_16_Protein_Sequence:
>Thiamine-phosphate pyrophosphorylase
MTRISREMMKELLSVYFIMGSNNTKADPVTVVQKALKGGATLYQFREKGGDALTGEARIK
FAEKAQAACREAGVPFIVNDDVELALNLKADGIHIGQEDANAKEVRAAIGDMILGVSAHT
MSEVKQAEEDGADYVGLGPIYPTETKKDTRAVQGVSLIEAVRRQGISIPIVGIGGITIDN
AAPVIQAGADGVSMISAISQAEDPESAARKFREEIQTYKTGR

# Drug_Target_16_Reaction:
2-methyl-4-amino-5-hydroxymethylpyrimidine diphosphate + 4-methyl-5-(2-phosphono-oxyethyl)thiazole = diphosphate + thiamine phosphate

# Drug_Target_16_Signals:
None

# Drug_Target_16_Specific_Function:
Condenses 4-methyl-5-(beta-hydroxyethyl)thiazole monophosphate (THZ-P) and 4-amino-5-hydroxymethyl pyrimidine pyrophosphate (HMP-PP) to form thiamine monophosphate (TMP)

# Drug_Target_16_SwissProt_ID:
P39594

# Drug_Target_16_SwissProt_Name:
THIE_BACSU

# Drug_Target_16_Synonyms:
EC 2.5.1.3
TMP pyrophosphorylase
TMP-PPase
Thiamine-phosphate synthase

# Drug_Target_16_Theoretical_pI:
4.99

# Drug_Target_16_Transmembrane_Regions:
None

# Drug_Target_17_Cellular_Location:
Secreted protein

# Drug_Target_17_Chromosome_Location:
Not Available

# Drug_Target_17_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_17_Essentiality:
Non-Essential

# Drug_Target_17_GenAtlas_ID:
ANG

# Drug_Target_17_GenBank_ID_Gene:
M11567

# Drug_Target_17_GenBank_ID_Protein:
178250

# Drug_Target_17_GeneCard_ID:
ANG

# Drug_Target_17_Gene_Name:
ANG

# Drug_Target_17_Gene_Sequence:
>444 bp
ATGGTGATGGGCCTGGGCGTTTTGTTGTTGGTCTTCGTGCTGGGTCTGGGTCTGACCCCA
CCGACCCTGGCTCAGGATAACTCCAGGTACACACACTTCCTGACCCAGCACTATGATGCC
AAACCACAGGGCCGGGATGACAGATACTGTGAAAGCATCATGAGGAGACGGGGCCTGACC
TCACCCTGCAAAGACATCAACACATTTATTCATGGCAACAAGCGCAGCATCAAGGCCATC
TGTGAAAACAAGAATGGAAACCCTCACAGAGAAAACCTAAGAATAAGCAAGTCTTCTTTC
CAGGTCACCACTTGCAAGCTACATGGAGGTTCCCCCTGGCCTCCATGCCAGTACCGAGCC
ACAGCGGGGTTCAGAAACGTTGTTGTTGCTTGTGAAAATGGCTTACCTGTCCACTTGGAT
CAGTCAATTTTCCGTCGTCCGTAA

# Drug_Target_17_General_Function:
Involved in nucleic acid binding

# Drug_Target_17_General_References:
11468363	Leonidas DD, Chavali GB, Jardine AM, Li S, Shapiro R, Acharya KR: Binding of phosphate and pyrophosphate ions at the active site of human angiogenin as revealed by X-ray crystallography. Protein Sci. 2001 Aug;10(8):1669-76.
11851402	Leonidas DD, Shapiro R, Subbarao GV, Russo A, Acharya KR: Crystallographic studies on the role of the C-terminal segment of human angiogenin in defining enzymatic potency. Biochemistry. 2002 Feb 26;41(8):2552-62.
11919285	Zhang J, Rosenberg HF: Diversifying selection of the tumor-growth promoter angiogenin in primate evolution. Mol Biol Evol. 2002 Apr;19(4):438-45.
12842050	Chavali GB, Papageorgiou AC, Olson KA, Fett JW, Hu G, Shapiro R, Acharya KR: The crystal structure of human angiogenin in complex with an antitumor neutralizing antibody. Structure. 2003 Jul;11(7):875-85.
1400510	Saxena SK, Rybak SM, Davey RT Jr, Youle RJ, Ackerman EJ: Angiogenin is a cytotoxic, tRNA-specific ribonuclease in the RNase A superfamily. J Biol Chem. 1992 Oct 25;267(30):21982-6.
2440105	Weiner HL, Weiner LH, Swain JL: Tissue distribution and developmental expression of the messenger RNA encoding angiogenin. Science. 1987 Jul 17;237(4812):280-2.
2866794	Strydom DJ, Fett JW, Lobb RR, Alderman EM, Bethune JL, Riordan JF, Vallee BL: Amino acid sequence of human tumor derived angiogenin. Biochemistry. 1985 Sep 24;24(20):5486-94.
2866795	Kurachi K, Davie EW, Strydom DJ, Riordan JF, Vallee BL: Sequence of the cDNA and gene for angiogenin, a human angiogenesis factor. Biochemistry. 1985 Sep 24;24(20):5494-9.
8159679	Acharya KR, Shapiro R, Allen SC, Riordan JF, Vallee BL: Crystal structure of human angiogenin reveals the structural basis for its functional divergence from ribonuclease. Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):2915-9.
9311977	Papageorgiou AC, Shapiro R, Acharya KR: Molecular recognition of human angiogenin by placental ribonuclease inhibitor--an X-ray crystallographic study at 2.0 A resolution. EMBO J. 1997 Sep 1;16(17):5162-77.
9461294	Lequin O, Thuring H, Robin M, Lallemand JY: Three-dimensional solution structure of human angiogenin determined by 1H,15N-NMR spectroscopy--characterization of histidine protonation states and pKa values. Eur J Biochem. 1997 Dec 15;250(3):712-26.
9918722	Leonidas DD, Shapiro R, Allen SC, Subbarao GV, Veluraja K, Acharya KR: Refined crystal structures of native human angiogenin and two active site variants: implications for the unique functional properties of an enzyme involved in neovascularisation during tumour growth. J Mol Biol. 1999 Jan 22;285(3):1209-33.

# Drug_Target_17_HGNC_ID:
HGNC:483

# Drug_Target_17_HPRD_ID:
00105

# Drug_Target_17_ID:
2149

# Drug_Target_17_Locus:
14q11.1-q11.2

# Drug_Target_17_Molecular_Weight:
16550

# Drug_Target_17_Name:
Angiogenin

# Drug_Target_17_Number_of_Residues:
147

# Drug_Target_17_PDB_ID:
2ANG

# Drug_Target_17_Pathway:
Not Available

# Drug_Target_17_Pfam_Domain_Function:
PF00074	RnaseA

# Drug_Target_17_Protein_Sequence:
>Angiogenin precursor
MVMGLGVLLLVFVLGLGLTPPTLAQDNSRYTHFLTQHYDAKPQGRDDRYCESIMRRRGLT
SPCKDINTFIHGNKRSIKAICENKNGNPHRENLRISKSSFQVTTCKLHGGSPWPPCQYRA
TAGFRNVVVACENGLPVHLDQSIFRRP

# Drug_Target_17_Reaction:
Not Available

# Drug_Target_17_Signals:
1-24

# Drug_Target_17_Specific_Function:
May function as a tRNA-specific ribonuclease that binds to actin on the surface of endothelial cells; once bound, angiogenin is endocytosed and translocated to the nucleus, thereby promoting the endothelial invasiveness necessary for blood vessel formation. Angiogenin induces vascularization of normal and malignant tissues. Abolishes protein synthesis by specifically hydrolyzing cellular tRNAs

# Drug_Target_17_SwissProt_ID:
P03950

# Drug_Target_17_SwissProt_Name:
ANGI_HUMAN

# Drug_Target_17_Synonyms:
Angiogenin precursor
EC 3.1.27.-
RNase 5
Ribonuclease 5

# Drug_Target_17_Theoretical_pI:
10.09

# Drug_Target_17_Transmembrane_Regions:
None

# Drug_Target_18_Cellular_Location:
Cytoplasm

# Drug_Target_18_Chromosome_Location:
Not Available

# Drug_Target_18_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_18_Essentiality:
Non-Essential

# Drug_Target_18_GenAtlas_ID:
Not Available

# Drug_Target_18_GenBank_ID_Gene:
X16279

# Drug_Target_18_GenBank_ID_Protein:
9914

# Drug_Target_18_GeneCard_ID:
Not Available

# Drug_Target_18_Gene_Name:
LACZ

# Drug_Target_18_Gene_Sequence:
>696 bp
ATGCCAATACCAAATAATCCAGGAGCTGGTGAAAATGCCTTTGATCCCGTTTTCGTAAAC
GATGACGATGGTTATGACCTTGATTCTTTTATGATCCCTGCACATTATAAAAAATATCTT
ACCAAGGTCTTAGTTCCAAATGGTGTCATAAAAAACCGTATTGAGAAATTGGCTTATGAT
ATTAAAAAGGTGTACAACAATGAAGAGTTTCATATTCTTTGTTTGTTGAAAGGTTCTCGT
GGTTTTTTCACTGCTCTCTTAAAGCATTTAAGTAGAATACATAATTATAGTGCCGTTGAG
ACGTCCAAACCATTATTTGGAGAACACTACGTACGTGTGAAATCCTATTGTAATGACCAA
TCAACAGGTACATTAGAAATTGTAAGTGAAGATTTATCTTGTTTAAAAGGAAAACATGTA
TTAATTGTTGAAGATATTATTGATACTGGTAAAACATTAGTAAAGTTTTGTGAATACTTA
AAGAAATTTGAAATAAAAACCGTTGCCATCGCTTGTCTTTTTATTAAAAGAACACCTTTG
TGGAATGGTTTTAAAGCTGATTTCGTTGGATTCTCAATTCCTGATCACTTTGTTGTTGGT
TATAGTTTAGACTATAATGAAATTTTCAGAGATCTTGACCATTGTTGTTTGGTTAATGAT
GAGGGAAAAAAGAAATATAAAGCAACTTCATTATAA

# Drug_Target_18_General_Function:
Nucleotide transport and metabolism

# Drug_Target_18_General_References:
10433693	Shi W, Li CM, Tyler PC, Furneaux RH, Cahill SM, Girvin ME, Grubmeyer C, Schramm VL, Almo SC: The 2.0 A structure of malarial purine phosphoribosyltransferase in complex with a transition-state analogue inhibitor. Biochemistry. 1999 Aug 3;38(31):9872-80.
2205541	Vasanthakumar G, Davis RL Jr, Sullivan MA, Donahue JP: Cloning and expression in Escherichia coli of a hypoxanthine-guanine phosphoribosyltransferase-encoding cDNA from Plasmodium falciparum. Gene. 1990 Jul 2;91(1):63-9.
2682528	Vasanthakumar G, Davis RL Jr, Sullivan MA, Donahue JP: Nucleotide sequence of cDNA clone for hypoxanthine-guanine phosphoribosyltransferase from Plasmodium falciparum. Nucleic Acids Res. 1989 Oct 25;17(20):8382.

# Drug_Target_18_HGNC_ID:
Not Available

# Drug_Target_18_HPRD_ID:
Not Available

# Drug_Target_18_ID:
2755

# Drug_Target_18_Locus:
Not Available

# Drug_Target_18_Molecular_Weight:
26349

# Drug_Target_18_Name:
Hypoxanthine-guanine-xanthine phosphoribosyltransferase

# Drug_Target_18_Number_of_Residues:
231

# Drug_Target_18_PDB_ID:
1CJB

# Drug_Target_18_Pathway:
Not Available

# Drug_Target_18_Pfam_Domain_Function:
PF00156	Pribosyltran

# Drug_Target_18_Protein_Sequence:
>Hypoxanthine-guanine-xanthine phosphoribosyltransferase
MPIPNNPGAGENAFDPVFVNDDDGYDLDSFMIPAHYKKYLTKVLVPNGVIKNRIEKLAYD
IKKVYNNEEFHILCLLKGSRGFFTALLKHLSRIHNYSAVETSKPLFGEHYVRVKSYCNDQ
STGTLEIVSEDLSCLKGKHVLIVEDIIDTGKTLVKFCEYLKKFEIKTVAIACLFIKRTPL
WNGFKADFVGFSIPDHFVVGYSLDYNEIFRDLDHCCLVNDEGKKKYKATSL

# Drug_Target_18_Reaction:
Not Available

# Drug_Target_18_Signals:
None

# Drug_Target_18_Specific_Function:
Works with guanine, hypoxanthine and xanthine

# Drug_Target_18_SwissProt_ID:
P20035

# Drug_Target_18_SwissProt_Name:
HGXR_PLAFG

# Drug_Target_18_Synonyms:
EC 2.4.2.-
HGPRT
HGXPRT
HGXPRTase

# Drug_Target_18_Theoretical_pI:
7.49

# Drug_Target_18_Transmembrane_Regions:
None

# Drug_Target_19_Cellular_Location:
Not Available

# Drug_Target_19_Chromosome_Location:
Not Available

# Drug_Target_19_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_19_Essentiality:
Non-Essential

# Drug_Target_19_GenAtlas_ID:
Not Available

# Drug_Target_19_GenBank_ID_Gene:
J05221

# Drug_Target_19_GenBank_ID_Protein:
149542

# Drug_Target_19_GeneCard_ID:
Not Available

# Drug_Target_19_Gene_Name:
fgs

# Drug_Target_19_Gene_Sequence:
>1287 bp
ATGAATTACACAGAAACGGTTGCCTACATTCATTCTTTTCCGCGTTTGGCCAAGACCGGT
GACCATCGGCGGATTTTAACGTTATTACATGCACTCGGCAATCCGCAGCAACAAGGGCGG
TATATTCACGTGACTGGTACTAATGGAAAAGGCTCAGCCGCTAATGCGATTGCACATGTC
CTTGAGGCAAGCGGTTTGACAGTCGGGTTATATACCTCGCCGTTTATCATGCGGTTTAAT
GAACGGATCATGATTGACCATGAACCGATTCCGGATGCTGCGTTAGTCAATGCGGTTGCG
TTTGTCAGGGCTGCACTGGAGCGGCTTCAGCAGCAACAAGCTGATTTTAACGTGACGGAA
TTTGAATTCATTACCGCGCTGGGCTATTGGTATTTTCGTCAGCGTCAGGTTGATGTTGCG
GTGATTGAAGTCGGTATTGGCGGCGACACGGATTCGACCAATGTCATCACGCCGGTTGTC
AGTGTTTTGACCGAGGTTGCTTTAGATCACCAGAAGTTGCTGGGGCATACGATTACGGCG
ATTGCCAAGCATAAGGCCGGTATTATCAAACGGGGTATTCCGGTTGTAACCGGTAACTTG
GTGCCGGATGCTGCTGCCGTTGTCGCAGCCAAGGTCGCGACAACAGGGAGTCAATGGTTG
CGTTTTGACCGCGATTTTTCGGTTCCTAAGGCTAAGCTTCACGGTTGGGGCCAACGGTTT
ACTTATGAAGACCAAGATGGACGTATTAGTGATTTGGAGGTGCCGTTGGTTGGCGATTAC
CAGCAACGTAATATGGCAATTGCGATTCAAACGGCAAAAGTGTATGCCAAGCAGACAGAA
TGGCCTTTGACGCCCCAGAATATTCGCCAAGGGCTTGCTGCCAGTCATTGGCCAGCCCGA
CTCGAAAAGATAAGTGATACGCCTTTGATCGTCATTGACGGGGCGCACAATCCGGATGGC
ATCAATGGTTTGATTACGGCGCTAAAGCAACTTTTTTCCCAACCCATTACTGTTATTGCC
GGCATCTTGGCGGATAAAGACTATGCGGCGATGGCGGATAGGCTGACCGCGGCATTTTCC
ACGGTTTATCTGGTTCCGGTGCCGGGGACGCCGCGCGCCTTGCCTGAGGCTGGTTATGAG
GCGCTGCACGAAGGTCGGTTAAAGGATTCGTGGCAGGAAGCATTGGCGGCGAGTCTTAAT
GATGTGCCGGATCAGCCGATTGTGATCACCGGTTCGCTGTATTTAGCCTCAGCTGTTCGT
CAAACTTTATTAGGGGGAAAATCATGA

# Drug_Target_19_General_Function:
Coenzyme transport and metabolism

# Drug_Target_19_General_References:
2105929	Toy J, Bognar AL: Cloning and expression of the gene encoding Lactobacillus casei folylpoly-gamma-glutamate synthetase in Escherichia coli and determination of its primary structure. J Biol Chem. 1990 Feb 15;265(5):2492-9.
9618466	Sun X, Bognar AL, Baker EN, Smith CA: Structural homologies with ATP- and folate-binding enzymes in the crystal structure of folylpolyglutamate synthetase. Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):6647-52.

# Drug_Target_19_HGNC_ID:
Not Available

# Drug_Target_19_HPRD_ID:
Not Available

# Drug_Target_19_ID:
2717

# Drug_Target_19_Locus:
Not Available

# Drug_Target_19_Molecular_Weight:
46590

# Drug_Target_19_Name:
Folylpolyglutamate synthase

# Drug_Target_19_Number_of_Residues:
428

# Drug_Target_19_PDB_ID:
1FGS

# Drug_Target_19_Pathway:
Not Available

# Drug_Target_19_Pfam_Domain_Function:
PF02875	Mur_ligase_C
PF08245	Mur_ligase_M

# Drug_Target_19_Protein_Sequence:
>Folylpolyglutamate synthase
MNYTETVAYIHSFPRLAKTGDHRRILTLLHALGNPQQQGRYIHVTGTNGKGSAANAIAHV
LEASGLTVGLYTSPFIMRFNERIMIDHEPIPDAALVNAVAFVRAALERLQQQQADFNVTE
FEFITALGYWYFRQRQVDVAVIEVGIGGDTDSTNVITPVVSVLTEVALDHQKLLGHTITA
IAKHKAGIIKRGIPVVTGNLVPDAAAVVAAKVATTGSQWLRFDRDFSVPKAKLHGWGQRF
TYEDQDGRISDLEVPLVGDYQQRNMAIAIQTAKVYAKQTEWPLTPQNIRQGLAASHWPAR
LEKISDTPLIVIDGAHNPDGINGLITALKQLFSQPITVIAGILADKDYAAMADRLTAAFS
TVYLVPVPGTPRALPEAGYEALHEGRLKDSWQEALAASLNDVPDQPIVITGSLYLASAVR
QTLLGGKS

# Drug_Target_19_Reaction:
ATP + tetrahydropteroyl-[gamma-Glu]n + L-glutamate = ADP + phosphate + tetrahydropteroyl-[gamma-Glu]n+1

# Drug_Target_19_Signals:
None

# Drug_Target_19_Specific_Function:
Conversion of folates to polyglutamate derivatives. It preferes 5,10-methylenetetrahydrofolate, rather than 10- formyltetrahydrofolate as folate substrate

# Drug_Target_19_SwissProt_ID:
P15925

# Drug_Target_19_SwissProt_Name:
FOLC_LACCA

# Drug_Target_19_Synonyms:
EC 6.3.2.17
FPGS
Folylpoly-gamma-glutamate synthetase
Tetrahydrofolate synthase
Tetrahydrofolylpolyglutamate synthase

# Drug_Target_19_Theoretical_pI:
7.02

# Drug_Target_19_Transmembrane_Regions:
None

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
Not Available

# Drug_Target_1_GenBank_ID_Protein:
Not Available

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
ISYNA1

# Drug_Target_1_Gene_Sequence:
Not Available

# Drug_Target_1_General_Function:
Not Available

# Drug_Target_1_General_References:
Not Available

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
7006

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
Not Available

# Drug_Target_1_Name:
Inositol-3-phosphate synthase 1

# Drug_Target_1_Number_of_Residues:
0

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
Not Available

# Drug_Target_1_Protein_Sequence:
Not Available

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
Not Available

# Drug_Target_1_Specific_Function:
Not Available

# Drug_Target_1_SwissProt_ID:
Q9NPH2

# Drug_Target_1_SwissProt_Name:
INO1_HUMAN

# Drug_Target_1_Synonyms:
Not Available

# Drug_Target_1_Theoretical_pI:
Not Available

# Drug_Target_1_Transmembrane_Regions:
Not Available

# Drug_Target_20_Cellular_Location:
Not Available

# Drug_Target_20_Chromosome_Location:
1

# Drug_Target_20_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_20_Essentiality:
Non-Essential

# Drug_Target_20_GenAtlas_ID:
Not Available

# Drug_Target_20_GenBank_ID_Gene:
AY165122

# Drug_Target_20_GenBank_ID_Protein:
33438760

# Drug_Target_20_GeneCard_ID:
MYH14

# Drug_Target_20_Gene_Name:
MYH14

# Drug_Target_20_Gene_Sequence:
>5988 bp
ATGGCAGCCGTGACCATGTCGGTGCCCGGGCGGAAGGCGCCCCCCAGGCCGGGCCCAGTG
CCCGAGGCGGCCCAGCCGTTCCTGTTCACGCCCCGCGGGCCCAGCGCGGGTGGCGGGCCT
GGCTCGGGCACCTCCCCGCAGGTGGAGTGGACGGCCCGGCGTCTCGTGTGGGTGCCTTCG
GAGCTTCACGGGTTCGAGGCGGCGGCGCTGCGGGACGAAGGCGAGGAGGAGGCGGAGGTG
GAGCTGGCGGAGAGCGGGAGGCGGCTGCGACTGCCGCGGGACCAGATCCAGCGCATGAAC
CCGCCCAAGTTCAGCAAGGCCGAGGACATGGCCGAGCTGACCTGCCTCAACGAGGCCTCG
GTCCTGCACAACCTCCGGGAGCGGTACTACTCCGGCCTCATCTACACGTACTCCGGCCTT
TTCTGTGTGGTCATCAACCCGTACAAGCAGCTTCCCATCTACACAGAAGCCATTGTGGAG
ATGTACCGGGGCAAGAAGCGCCACGAGGTGCCACCCCACGTGTACGCAGTGACCGAGGGG
GCCTATCGGAGCATGCTGCAGGATCGTGAGGACCAGTCCATTCTCTGCACTGGAGAGTCT
GGAGCTGGGAAGACGGAAAACACCAAGAAGGTCATCCAGTACCTCGCCCACGTGGCATCG
TCTCCAAAGGGCAGGAAGGAGCCGGGTGTCCCCGGTGAGCTGGAGCGGCAGCTGCTTCAG
GCCAACCCCATCCTAGAGGCCTTTGGCAATGCCAAGACAGTGAAGAATGACAACTCCTCC
CGATTCGGCAAATTCATCCGCATCAACTTTGATGTTGCCGGGTACATCGTGGGCGCCAAC
ATTGAGACCTACCTGCTGGAGAAGTCGCGGGCCATCCGCCAGGCCAAGGACGAGTGCAGC
TTCCACATCTTCTACCAGCTGCTGGGGGGCGCTGGAGAGCAGCTCAAAGCCGACCTCCTC
CTCGAGCCCTGCTCCCACTACCGGTTCCTGACCAACGGGCCGTCATCCTCTCCCGGCCAG
GAGCGGGAACTCTTCCAGGAGACGCTGGAGTCGCTGCGGGTCCTGGGATTCAGCCACGAG
GAAATCATCTCCATGCTGCGGATGGTCTCAGCAGTTCTCCAGTTTGGCAACATTGCCTTG
AAGAGAGAACGGAACACCGATCAAGCCACCATGCCTGACAACACAGCTGCACAGAAGCTC
TGCCGCCTCTTGGGACTGGGGGTGACGGATTTCTCCCGAGCCTTGCTCACCCCTCGCATC
AAAGTTGGCCGAGACTATGTGCAGAAAGCCCAGACTAAGGAACAGGCTGACTTCGCGCTG
GAGGCCCTGGCCAAGGCCACCTACGAGCGCCTCTTCCGCTGGCTGGTTCTGCGCCTCAAC
CGGGCCTTGGACCGCAGCCCCCGCCAAGGCGCCTCCTTCCTGGGCATCCTGGACATCGCG
GGCTTTGAGATCTTCCAGCTGAACTCCTTCGAGCAGCTCTGCATCAACTACACCAACGAG
AAGCTGCAGCAGCTCTTCAACCACACCATGTTCGTGCTGGAGCAGGAGGAGTACCAGCGT
GAGGGCATCCCCTGGACCTTCCTCGACTTTGGCCTCGACCTGCAGCCCTGCATCGACCTC
ATCGAGCGGCCGGCCAACCCCCCTGGACTCCTGGCCCTGCTGGATGAGGAGTGCTGGTTC
CCGAAGGCCACAGACAAGTCGTTTGTGGAGAAGGTAGCCCAGGAGCAGGGCGGCCACCCC
AAGTTCCAGCGGCCGAGGCACCTGCGGGATCAGGCCGACTTCAGTGTTCTCCACTACGCG
GGCAAGGTCGACTACAAGGCCAACGAGTGGCTGATGAAAAACATGGACCCTCTGAATGAC
AACGTCGCAGCCTTGCTCCACCAGAGCACAGACCGGCTGACGGCAGAGATCTGGAAAGAC
GTGGAGGGCATCGTGGGGCTGGAACAGGTGAGCAGCCTGGGCGACGGCCCACCAGGTGGC
CGCCCCCGTCGGGGTATGTTCCGGACAGTGGGACAGCTCTACAAGGAGTCCCTGAGCCGC
CTCATGGCCACACTCAGCAACACCAACCCCAGTTTTGTCCGGTGCATTGTCCCCAACCAC
GAGAAGAGGGCCGGGAAGCTGGAGCCACGGCTGGTGCTGGACCAGCTTCGCTGCAACGGG
GTCCTGGAGGGCATCCGCATCTGTCGCCAGGGCTTCCCCAACCGCATCCTCTTCCAGGAG
TTCCGGCAGCGATACGAGATCCTGACACCCAATGCCATCCCCAAGGGCTTCATGGATGGG
AAGCAGGCCTGTGAAAAGATGATCCAGGCGCTGGAACTGGACCCCAACCTCTACCGCGTG
GGACAGAGCAAGATCTTCTTCCGGGCTGGGGTCCTGGCCCAGCTGGAAGAGGAGCGAGAC
CTGAAGGTCACCGACATCATCGTCTCCTTCCAGGCAGCTGCCCGGGGATACCTGGCTCGC
AGGGCCTTCCAGAAGCGCCAGCAGCAGCAGAGCGCCCTGAGGGTGATGCAGCGGAACTGC
GCGGCCTACCTCAAGCTGAGACACTGGCAGTGGTGGCGGCTGTTTACCAAGGTGAAGCCA
CTGCTGCAGGTGACGCGGCAGGATGAGGTGCTGCAGGCACGGGCCCAGGAGCTGCAGAAA
GTGCAGGAGCTACAGCAGCAGAGCGCCCGCGAAGTTGGGGAGCTCCAGGGCCGAGTGGCA
CAGCTGGAAGAGGAGCGCGCCCGCCTGGCAGAGCAATTGCGAGCAGAGGCAGAACTGTGT
GCAGAGGCCGAGGAGACGCGGGGGAGGCTGGCAGCCCGCAAGCAGGAGCTGGAGCTGGTG
GTGTCAGAGCTGGAGGCTCGCGTGGGCGAGGAGGAGGAGTGCAGCCGTCAAATGCAAACC
GAGAAGAAGAGGCTACAGCAGCACATACAGGAGCTAGAGGCCCACCTTGAGGCTGAGGAG
GGTGCGCGGCAGAAGCTGCAGCTGGAGAAGGTGACGACAGAGGCAAAAATGAAGAAATTT
GAAGAGGACCTGCTGCTCCTGGAAGACCAGAATTCCAAGCTGAGCAAGAGCGGAAGCTGC
TGGAAGATCGTCTGGCCGAGTTCTCATCCCAGGCAGCTGAGGAGGAGGAGAAGGTCAAGA
GCCTCAATAAGCTACGGCTCAAATATGAGGCCACAATCGCAGACATGGAGGGACCGCCTA
CGGAAGGAGGAGAAGGGTCGCCAGGAGCTGGAGAAGCTGAAGCGGAGGCTGGATGGGGAG
AGCTCAGAGCTGCAGGAGCAGATGGTGGAGCAGCAACAGCGGGCAGAGGAGCTGCGGGCC
CAGCTGGGCCGGAAGGAGGAGGAGCTGCAGGCTGCCCTGGCCAGGGCAGAAGACGAGGGT
GGGGCCCGGGCCCAGCTGCTGAAATCCCTGCGGGAGGCTCAAGCAGCCCTGGCCGAGGCC
CAGGAGGACCTGGAGTCTGAGCGTGTGGCCAGGACCAAGGCGGAGAAGCAGCGCCGGGAC
CTGGGCGAGGAGCTGGAGGCGCTGCGGGGCGAGCTGGAGGACACGCTGGACTCCACCAAC
GCACAGCAGGAGCTCCGGTCCAAGAGGGAACAGGAGGTGACGGAGCTGAAGAAGACTCTG
GAGGAGGAGACTCGCATCCACGAGGCGGCAGTGCAGGAGCTGAGGCAGCGCCACGGCCAG
GCCCTGGGGGAGCTGGCGGAGCAGCTGGAGCAGGCCCGGAGGGGCAAAGGTGCATGGGAG
AAGACCCGGCTGGCCCTGGAGGCCGAGGTGTCCGAGCTGCGGGCAGAACTGAGCAGCCTG
CAGACTGCACGTCAGGAGGGTGAGCAGCGGAGGCGCCGCCTGGAGTTACAGCTGCAGGAG
GTGCAGGGCCGGGCTGGTGATGGGGAGAGGGCACGAGCGGAGGCTGCTGAGAAGCTGCAG
CGAGCCCAGGCTGAACTGGAGAATGTGTCTGGGGCGCTGAACGAGGCTGAGTCCAAAACC
ATCCGTCTTAGCAAGGAGCTGAGCAGCACAGAAGCCCAGCTGCACGATGCCCAGGAGCTG
CTGCAGGAGGAGACCAGGGCGAAATTGGCCTTGGGGTCCCGGGTGCGAGCCATGGAGGCT
GAGGCAGCCGGGCTGCGTGAGCAGCTGGAGGAGGAGGCAGCTGCCAGGGAACGGGCGGGC
CGTGAACTGCAGACTGCCCAGGCCCAGCTTTCCGAGTGGCGGCGGCGCCAGGAGGAGGAG
GCAGGGGCACTGGAGGCAGGGGAGGAGGCACGGCGCCGGGCAGCCCGGGAGGCCGAGGCC
CTGACCCAGCGCCTGGCAGAAAAGACAGAGACCGTGGATCGGCTGGAGCGGGGCCGCCGC
CGGCTGCAGCAGGAGCTGGACGACGCCACCATGGACCTGGAGCAGCAGCGGCAGCTTGTG
AGCACCCTGGAGAAGAAGCAGCGCAAGTTTGACCAGCTTCTGGCAGAGGAGAAGGCAGCT
GTACTTCGGGCAGTGGAGGAACGTGAGCGGGCCGAGGCAGAGGGCCGGGAGCGTGAGGCT
CGGGCCCTGTCACTGACACGGGCACTGGAGGAGGAGCAGGAGGCACGTGAGGAGCTGGAG
CGGCAGAACCGGGCCCTGCGGGCTGAGCTGGAGGCACTGCTGAGCAGCAAGGATGACGTC
GGCAAGAGCGTGCATGAGCTGGAACGAGCCTGCCGGGTAGCAGAACAGGCAGCCAATGAT
CTGCGAGCACAGGTGACAGAACTGGAGGATGAGCTGACAGCGGCCGAGGATGCCAAGCTG
CGTCTGGAGGTGACTGTGCAGGCTCTCAAGACTCAGCATGAGCGTGACCTGCAGGGCCGT
GATGAGGCTGGTGAAGAGAGGCGGAGGCAGCTGGCCAAGCAGCTGAGAGATGCAGAGGTG
GAGCGGGATGAGGAGCGGAAGCAGCGCACTCTGGCCGTGGCTGCCCGCAAGAAGCTGGAG
GGAGAGCTGGAGGAGCTGAAGGCTCAGATGGCCTCTGCCGGCCAGGGCAAGGAGGAGGCG
GTGAAGCAGCTTCGCAAGATGCAGGCCCAGATGAAGGAGCTATGGCGGGAGGTGGAGGAG
ACACGCACCTCCCGGGAGGAGATCTTCTCCCAGAATCGGGAAAGTGAAAAGCGCCTCAAG
GGCCTGGAGGCTGAGGTGCTGCGGCTGCAGGAGGAACTGGCCGCCTCGGACCGTGCTCGG
CGGCAGGCCCAGCAGGACCGGGATGAGATGGCAGATGAGGTGGCCAATGGTAACCTTAGC
AAGGCAGCCATTCTGGAGGAGAAGCGTCAGCTGGAGGGGCGCCTGGGGCAGTTGGAGGAA
GAGCTGGAGGAGGAGCAGAGCAACTCAGAGCTGCTCAATGACCGCTACCGCAAGCTGCTC
CTGCAGGTAGAGTCACTGACCACAGAGCTGTCAGCTGAGCGCAGTTTCTCAGCCAAGGCA
GAGAGCGGGCGGCAGCAGCTGGAACGGCAGATCCAGGAGCTACGGGGACGCCTGGGTGAG
GAGGATGCTGGGGCCCGTGCCCGCCACAAGATGACCATTGCTGCCCTTGAGTCTAAGTTG
GCCCAGGCTGAGGAGCAGCTAGAGCAAGAGACCAGAGAGCGCATCCTCTCTGGAAAGCTG
GTGCGCAGAGCTGAGAAGCGGCTTAAAGAGGTGGTGCTCCAGGTGGAGGAGGAGCGGAGG
GTGGCTGACCAGCTCCGGGACCAGCTGGAGAAGGGAAACCTTCGAGTCAAGCAGCTGAAG
CGGCAGCTGGAGGAGGCCGAGGAGGAGGCATCCCGGGCTCAGGCTGGCCGCCGGAGGCTG
CAGCGTGAGCTGGAAGATGTCACAGAGTCGGCCGAGTCCATGAACCGTGAAGTGACCACA
CTGAGGAACCGGCTTCGACGCGGCCCCCTCACCTTCACCACCCGCACGGTGCGCCAGGTC
TTCCGACTAGAGGAGGGCGTGGCATCCGACGAGGAGGCAGAGGAAGCACAGCCTGGGTCT
GGGCCATCCCCGGAGCCTGAGGGGTCCCCACCAGCCCACCCCCAGTGA

# Drug_Target_20_General_Function:
Cell cycle control, cell division, chromosome partitioning

# Drug_Target_20_General_References:
11919279	Desjardins PR, Burkman JM, Shrager JB, Allmond LA, Stedman HH: Evolutionary implications of three novel members of the human sarcomeric myosin heavy chain gene family. Mol Biol Evol. 2002 Apr;19(4):375-93.
12909352	Leal A, Endele S, Stengel C, Huehne K, Loetterle J, Barrantes R, Winterpacht A, Rautenstrauss B: A novel myosin heavy chain gene in human chromosome 19q13.3. Gene. 2003 Jul 17;312:165-71.
14594953	Golomb E, Ma X, Jana SS, Preston YA, Kawamoto S, Shoham NG, Goldin E, Conti MA, Sellers JR, Adelstein RS: Identification and characterization of nonmuscle myosin II-C, a new member of the myosin II family. J Biol Chem. 2004 Jan 23;279(4):2800-8. Epub 2003 Nov 1.
14702039	Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K, Kimura K, Makita H, Sekine M, Obayashi M, Nishi T, Shibahara T, Tanaka T, Ishii S, Yamamoto J, Saito K, Kawai Y, Isono Y, Nakamura Y, Nagahari K, Murakami K, Yasuda T, Iwayanagi T, Wagatsuma M, Shiratori A, Sudo H, Hosoiri T, Kaku Y, Kodaira H, Kondo H, Sugawara M, Takahashi M, Kanda K, Yokoi T, Furuya T, Kikkawa E, Omura Y, Abe K, Kamihara K, Katsuta N, Sato K, Tanikawa M, Yamazaki M, Ninomiya K, Ishibashi T, Yamashita H, Murakawa K, Fujimori K, Tanai H, Kimata M, Watanabe M, Hiraoka S, Chiba Y, Ishida S, Ono Y, Takiguchi S, Watanabe S, Yosida M, Hotuta T, Kusano J, Kanehori K, Takahashi-Fujii A, Hara H, Tanase TO, Nomura Y, Togiya S, Komai F, Hara R, Takeuchi K, Arita M, Imose N, Musashino K, Yuuki H, Oshima A, Sasaki N, Aotsuka S, Yoshikawa Y, Matsunawa H, Ichihara T, Shiohata N, Sano S, Moriya S, Momiyama H, Satoh N, Takami S, Terashima Y, Suzuki O, Nakagawa S, Senoh A, Mizoguchi H, Goto Y, Shimizu F, Wakebe H, Hishigaki H, Watanabe T, Sugiyama A, Takemoto M, Kawakami B, Yamazaki M, Watanabe K, Kumagai A, Itakura S, Fukuzumi Y, Fujimori Y, Komiyama M, Tashiro H, Tanigami A, Fujiwara T, Ono T, Yamada K, Fujii Y, Ozaki K, Hirao M, Ohmori Y, Kawabata A, Hikiji T, Kobatake N, Inagaki H, Ikema Y, Okamoto S, Okitani R, Kawakami T, Noguchi S, Itoh T, Shigeta K, Senba T, Matsumura K, Nakajima Y, Mizuno T, Morinaga M, Sasaki M, Togashi T, Oyama M, Hata H, Watanabe M, Komatsu T, Mizushima-Sugano J, Satoh T, Shirai Y, Takahashi Y, Nakagawa K, Okumura K, Nagase T, Nomura N, Kikuchi H, Masuho Y, Yamashita R, Nakai K, Yada T, Nakamura Y, Ohara O, Isogai T, Sugano S: Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet. 2004 Jan;36(1):40-5. Epub 2003 Dec 21.
15489334	Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.
15498874	Wan D, Gong Y, Qin W, Zhang P, Li J, Wei L, Zhou X, Li H, Qiu X, Zhong F, He L, Yu J, Yao G, Jiang H, Qian L, Yu Y, Shu H, Chen X, Xu H, Guo M, Pan Z, Chen Y, Ge C, Yang S, Gu J: Large-scale cDNA transfection screening for genes related to cancer development and progression. Proc Natl Acad Sci U S A. 2004 Nov 2;101(44):15724-9. Epub 2004 Oct 21.
17974005	Bechtel S, Rosenfelder H, Duda A, Schmidt CP, Ernst U, Wellenreuther R, Mehrle A, Schuster C, Bahr A, Blocker H, Heubner D, Hoerlein A, Michel G, Wedler H, Kohrer K, Ottenwalder B, Poustka A, Wiemann S, Schupp I: The full-ORF clone resource of the German cDNA Consortium. BMC Genomics. 2007 Oct 31;8:399.
18083107	Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, Nardone J, Lee K, Reeves C, Li Y, Hu Y, Tan Z, Stokes M, Sullivan L, Mitchell J, Wetzel R, Macneill J, Ren JM, Yuan J, Bakalarski CE, Villen J, Kornhauser JM, Smith B, Li D, Zhou X, Gygi SP, Gu TL, Polakiewicz RD, Rush J, Comb MJ: Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007 Dec 14;131(6):1190-203.

# Drug_Target_20_HGNC_ID:
GNC:23212

# Drug_Target_20_HPRD_ID:
Not Available

# Drug_Target_20_ID:
6395

# Drug_Target_20_Locus:
19q13.33

# Drug_Target_20_Molecular_Weight:
227999.8

# Drug_Target_20_Name:
Myosin-14

# Drug_Target_20_Number_of_Residues:
1995

# Drug_Target_20_PDB_ID:
Not Available

# Drug_Target_20_Pathway:
Not Available

# Drug_Target_20_Pfam_Domain_Function:
PF00063	Myosin_head
PF00612	IQ
PF01576	Myosin_tail_1
PF02736	Myosin_N

# Drug_Target_20_Protein_Sequence:
>Myosin-14
MAAVTMSVPGRKAPPRPGPVPEAAQPFLFTPRGPSAGGGPGSGTSPQVEWTARRLVWVPS
ELHGFEAAALRDEGEEEAEVELAESGRRLRLPRDQIQRMNPPKFSKAEDMAELTCLNEAS
VLHNLRERYYSGLIYTYSGLFCVVINPYKQLPIYTEAIVEMYRGKKRHEVPPHVYAVTEG
AYRSMLQDREDQSILCTGESGAGKTENTKKVIQYLAHVASSPKGRKEPGVPGELERQLLQ
ANPILEAFGNAKTVKNDNSSRFGKFIRINFDVAGYIVGANIETYLLEKSRAIRQAKDECS
FHIFYQLLGGAGEQLKADLLLEPCSHYRFLTNGPSSSPGQERELFQETLESLRVLGFSHE
EIISMLRMVSAVLQFGNIALKRERNTDQATMPDNTAAQKLCRLLGLGVTDFSRALLTPRI
KVGRDYVQKAQTKEQADFALEALAKATYERLFRWLVLRLNRALDRSPRQGASFLGILDIA
GFEIFQLNSFEQLCINYTNEKLQQLFNHTMFVLEQEEYQREGIPWTFLDFGLDLQPCIDL
IERPANPPGLLALLDEECWFPKATDKSFVEKVAQEQGGHPKFQRPRHLRDQADFSVLHYA
GKVDYKANEWLMKNMDPLNDNVAALLHQSTDRLTAEIWKDVEGIVGLEQVSSLGDGPPGG
RPRRGMFRTVGQLYKESLSRLMATLSNTNPSFVRCIVPNHEKRAGKLEPRLVLDQLRCNG
VLEGIRICRQGFPNRILFQEFRQRYEILTPNAIPKGFMDGKQACEKMIQALELDPNLYRV
GQSKIFFRAGVLAQLEEERDLKVTDIIVSFQAAARGYLARRAFQKRQQQQSALRVMQRNC
AAYLKLRHWQWWRLFTKVKPLLQVTRQDEVLQARAQELQKVQELQQQSAREVGELQGRVA
QLEEERARLAEQLRAEAELCAEAEETRGRLAARKQELELVVSELEARVGEEEECSRQMQT
EKKRLQQHIQELEAHLEAEEGARQKLQLEKVTTEAKMKKFEEDLLLLEDQNSKLSKSGSC
WKIVWPSSHPRQLRRRRRSRASISYGSNMRPQSQTWRDRLRKEEKGRQELEKLKRRLDGE
SSELQEQMVEQQQRAEELRAQLGRKEEELQAALARAEDEGGARAQLLKSLREAQAALAEA
QEDLESERVARTKAEKQRRDLGEELEALRGELEDTLDSTNAQQELRSKREQEVTELKKTL
EEETRIHEAAVQELRQRHGQALGELAEQLEQARRGKGAWEKTRLALEAEVSELRAELSSL
QTARQEGEQRRRRLELQLQEVQGRAGDGERARAEAAEKLQRAQAELENVSGALNEAESKT
IRLSKELSSTEAQLHDAQELLQEETRAKLALGSRVRAMEAEAAGLREQLEEEAAARERAG
RELQTAQAQLSEWRRRQEEEAGALEAGEEARRRAAREAEALTQRLAEKTETVDRLERGRR
RLQQELDDATMDLEQQRQLVSTLEKKQRKFDQLLAEEKAAVLRAVEERERAEAEGREREA
RALSLTRALEEEQEAREELERQNRALRAELEALLSSKDDVGKSVHELERACRVAEQAAND
LRAQVTELEDELTAAEDAKLRLEVTVQALKTQHERDLQGRDEAGEERRRQLAKQLRDAEV
ERDEERKQRTLAVAARKKLEGELEELKAQMASAGQGKEEAVKQLRKMQAQMKELWREVEE
TRTSREEIFSQNRESEKRLKGLEAEVLRLQEELAASDRARRQAQQDRDEMADEVANGNLS
KAAILEEKRQLEGRLGQLEEELEEEQSNSELLNDRYRKLLLQVESLTTELSAERSFSAKA
ESGRQQLERQIQELRGRLGEEDAGARARHKMTIAALESKLAQAEEQLEQETRERILSGKL
VRRAEKRLKEVVLQVEEERRVADQLRDQLEKGNLRVKQLKRQLEEAEEEASRAQAGRRRL
QRELEDVTESAESMNREVTTLRNRLRRGPLTFTTRTVRQVFRLEEGVASDEEAEEAQPGS
GPSPEPEGSPPAHPQ

# Drug_Target_20_Reaction:
Not Available

# Drug_Target_20_Signals:
None

# Drug_Target_20_Specific_Function:
Cellular myosin that appears to play a role in cytokinesis, cell shape, and specialized functions such as secretion and capping (By similarity)

# Drug_Target_20_SwissProt_ID:
Q7Z406

# Drug_Target_20_SwissProt_Name:
MYH14_HUMAN

# Drug_Target_20_Synonyms:
Myosin heavy chain 14
Myosin heavy chain, non-muscle IIc
NMHC II-C
Non-muscle myosin heavy chain IIc

# Drug_Target_20_Theoretical_pI:
5.69

# Drug_Target_20_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Not Available

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
Not Available

# Drug_Target_2_GenBank_ID_Protein:
Not Available

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
PPA1

# Drug_Target_2_Gene_Sequence:
Not Available

# Drug_Target_2_General_Function:
Not Available

# Drug_Target_2_General_References:
Not Available

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
6968

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
Not Available

# Drug_Target_2_Name:
Inorganic pyrophosphatase

# Drug_Target_2_Number_of_Residues:
0

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
Not Available

# Drug_Target_2_Protein_Sequence:
Not Available

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
Not Available

# Drug_Target_2_Specific_Function:
Not Available

# Drug_Target_2_SwissProt_ID:
Q15181

# Drug_Target_2_SwissProt_Name:
IPYR_HUMAN

# Drug_Target_2_Synonyms:
Not Available

# Drug_Target_2_Theoretical_pI:
Not Available

# Drug_Target_2_Transmembrane_Regions:
Not Available

# Drug_Target_3_Cellular_Location:
Not Available

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
Not Available

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
Not Available

# Drug_Target_3_GenBank_ID_Gene:
L42023

# Drug_Target_3_GenBank_ID_Protein:
Not Available

# Drug_Target_3_GeneCard_ID:
Not Available

# Drug_Target_3_Gene_Name:
ispF

# Drug_Target_3_Gene_Sequence:
>477 bp
TTATTGTCGGATTAAAAGAGCAACGGCTTCACAAGCAATCCCCTCTTGTCTTCCTGTAAA
GCCTAATTTTTCGGTAGTCGTTGCTTTTACATTAACTTGCTCAATATCGCATTGGAGATC
TTCAGCTATTTTGGCACGCATTGCATCAATATGTGGGCGCATTTTAGGTGCTTGAGCGAT
GATGGTAATATCAACATTACCTATTTTATATCCCTTTTCTTGTACTTGACGAAACGCTTC
ACGCAGTAAGCCTCGACTATCCGCATTTTTATATTGCATATCAGTATCGGGGAAAAGTTT
TCCAATATCGCCTAAAGCCGCAGCCCCTAAGATTGCATCAGTTAATGCGTGTAATGCCAC
ATCGCCATCTGAGTGCGCAATAAAGCCCGTATGATAAGGCACTTCTACACCACCAATAAT
TAATGGACGATCTTCGCCAAAAGCGTGAACATCAAAGCCGTGTCCAATTCTGATCAT

# Drug_Target_3_General_Function:
Involved in 2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase activity

# Drug_Target_3_General_References:
7542800	Fleischmann RD, Adams MD, White O, Clayton RA, Kirkness EF, Kerlavage AR, Bult CJ, Tomb JF, Dougherty BA, Merrick JM, et al.: Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. Science. 1995 Jul 28;269(5223):496-512.
9719565	Fountoulakis M, Juranville JF, Roder D, Evers S, Berndt P, Langen H: Reference map of the low molecular mass proteins of Haemophilus influenzae. Electrophoresis. 1998 Jul;19(10):1819-27.

# Drug_Target_3_HGNC_ID:
Not Available

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
4620

# Drug_Target_3_Locus:
Not Available

# Drug_Target_3_Molecular_Weight:
17194

# Drug_Target_3_Name:
2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase

# Drug_Target_3_Number_of_Residues:
158

# Drug_Target_3_PDB_ID:
1JN1

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF02542	YgbB

# Drug_Target_3_Protein_Sequence:
>2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase
MIRIGHGFDVHAFGEDRPLIIGGVEVPYHTGFIAHSDGDVALHALTDAILGAAALGDIGK
LFPDTDMQYKNADSRGLLREAFRQVQEKGYKIGNVDITIIAQAPKMRPHIDAMRAKIAED
LQCDIEQVNVKATTTEKLGFTGRQEGIACEAVALLIRQ

# Drug_Target_3_Reaction:
Not Available

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
Converts 4-diphosphocytidyl-2-C-methyl-D-erythritol 2- phosphate into 2-C-methyl-D-erythritol 2,4-cyclodiphosphate (MECDP) and CMP (By similarity)

# Drug_Target_3_SwissProt_ID:
P44815

# Drug_Target_3_SwissProt_Name:
ISPF_HAEIN

# Drug_Target_3_Synonyms:
EC 4.6.1.12
MECDP-synthase
MECPS

# Drug_Target_3_Theoretical_pI:
5.92

# Drug_Target_3_Transmembrane_Regions:
None

# Drug_Target_4_Cellular_Location:
Cytoplasmic

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
Not Available

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
Not Available

# Drug_Target_4_GenBank_ID_Gene:
AF012735

# Drug_Target_4_GenBank_ID_Protein:
Not Available

# Drug_Target_4_GeneCard_ID:
Not Available

# Drug_Target_4_Gene_Name:
Not Available

# Drug_Target_4_Gene_Sequence:
>1245 bp
ATGATCTCACTCGCCGACCTCCAGCGCCGCATCGAAACGGGCGAGCTGTCGCCTAACGCA
GCCATCGCCCAGTCGCACGCGGCGATCGAGGCGCGGGAGAAGGAGGTCCATGCCTTCGTC
CGCCACGACAAGTCGGCAAGAGCGCAAGCCTCCGGCCCGCTGCGCGGTATCGCCGTCGGC
ATCAAGGACATCATCGACACCGCCAACATGCCCACCGAGATGGGCTCGGAGATCTATCGC
GGCTGGCAGCCGCGCAGCGACGCGCCTGTCGTGATGATGCTGAAGCGGGCGGGGGCCACC
ATCATCGGCAAGACCACCACCACGGCGTTCGCCTCGCGCGATCCGACGGCGACGCTCAAT
CCGCACAATACCGGCCATTCCCCGGGCGGCTCGTCCTCGGGCTCGGCGGCGGCGGTCGGC
GCCGGCATGATCCCGCTGGCGCTGGGCACCCAGACCGGCGGCTCGGTGATCCGGCCCGCC
GCCTATTGCGGGACGGCCGCGATCAAGCCGTCGTTCCGCATGCTGCCGACGGTCGGCGTG
AAGTGCTATTCGTGGGCGCTCGACACGGTCGGCCTGTTCGGCGCGCGCGCGGAGGATCTC
GCGCGCGGACTGCTGGCGATGACCGGCCGCAGCGAATTCTCCGGCATCGTCCCGGCCAAG
GCACCGCGCATCGGCGTGGTCAGGCAGGAGTTCGCCGGCGCTGTCGAGCCGGCGGCCGAG
CAGGGCCTGCAAGCCGCGATCAAGGCGGCCGAGCGGGCCGGGGCCAGTGTTCAGGCCATC
GATCTGCCCGAGGCGGTGCATGAGGCCTGGCGCATCCATCCCATCATCCAGGATTTCGAG
GCGCATCGCGCGCTCGCCTGGGAGTTTTCCGAGCATCACGACGAGATCGCGCCGATGCTG
CGCGCCAGTCTCGATGCGACGGTCGGGCTCACGCCGAAGGAATATGACGAGGCGCGCCGG
ATCGGCCGCCGTGGCCGCCGCGAGCTTGGCGAAGTGTTCGAGGGCGTCGACGTGCTCTTG
ACCTATTCGGCGCCGGGCACCGCGCCGGCCAAGGCTCTCGCGAGCACCGGCGACCCTCGC
TACAACCGGCTCTGGACGCTGATGGGCAATCCTTGCGTCAACGTGCCGGTGCTGAAGGTC
GGTGGCCTGCCGATCGGCGTGCAGGTGATCGCGCGCTTCGGCAACGACGCACATGCGCTT
GCGACGGCGTGGTTCCTGGAGGATGCGCTGGCGAAATCAGGCTAG

# Drug_Target_4_General_Function:
Involved in carbon-nitrogen ligase activity, with glutamine as amido-N-donor

# Drug_Target_4_General_References:
12597275	Kaneko T, Nakamura Y, Sato S, Minamisawa K, Uchiumi T, Sasamoto S, Watanabe A, Idesawa K, Iriguchi M, Kawashima K, Kohara M, Matsumoto M, Shimpo S, Tsuruoka H, Wada T, Yamada M, Tabata S: Complete genomic sequence of nitrogen-fixing symbiotic bacterium Bradyrhizobium japonicum USDA110. DNA Res. 2002 Dec 31;9(6):189-97.
12711609	Shin S, Yun YS, Koo HM, Kim YS, Choi KY, Oh BH: Characterization of a novel Ser-cisSer-Lys catalytic triad in comparison with the classical Ser-His-Asp triad. J Biol Chem. 2003 Jul 4;278(27):24937-43. Epub 2003 Apr 23.

# Drug_Target_4_HGNC_ID:
Not Available

# Drug_Target_4_HPRD_ID:
Not Available

# Drug_Target_4_ID:
4600

# Drug_Target_4_Locus:
Not Available

# Drug_Target_4_Molecular_Weight:
43682

# Drug_Target_4_Name:
Malonamidase E2

# Drug_Target_4_Number_of_Residues:
414

# Drug_Target_4_PDB_ID:
1OBL

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF01425	Amidase

# Drug_Target_4_Protein_Sequence:
>Malonamidase E2
MISLADLQRRIETGELSPNAAIAQSHAAIEAREKEVHAFVRHDKSARAQASGPLRGIAVG
IKDIIDTANMPTEMGSEIYRGWQPRSDAPVVMMLKRAGATIIGKTTTTAFASRDPTATLN
PHNTGHSPGGSSSGSAAAVGAGMIPLALGTQTGGSVIRPAAYCGTAAIKPSFRMLPTVGV
KCYSWALDTVGLFGARAEDLARGLLAMTGRSEFSGIVPAKAPRIGVVRQEFAGAVEPAAE
QGLQAAIKAAERAGASVQAIDLPEAVHEAWRIHPIIQDFEAHRALAWEFSEHHDEIAPML
RASLDATVGLTPKEYDEARRIGRRGRRELGEVFEGVDVLLTYSAPGTAPAKALASTGDPR
YNRLWTLMGNPCVNVPVLKVGGLPIGVQVIARFGNDAHALATAWFLEDALAKSG

# Drug_Target_4_Reaction:
Not Available

# Drug_Target_4_Signals:
None

# Drug_Target_4_Specific_Function:
Not Available

# Drug_Target_4_SwissProt_ID:
Q9ZIV5

# Drug_Target_4_SwissProt_Name:
Q9ZIV5_BRAJA

# Drug_Target_4_Synonyms:
Not Available

# Drug_Target_4_Theoretical_pI:
8.13

# Drug_Target_4_Transmembrane_Regions:
None

# Drug_Target_5_Cellular_Location:
Not Available

# Drug_Target_5_Chromosome_Location:
Not Available

# Drug_Target_5_Drug_References:
Not Available

# Drug_Target_5_Essentiality:
Non-Essential

# Drug_Target_5_GenAtlas_ID:
Not Available

# Drug_Target_5_GenBank_ID_Gene:
AE008789

# Drug_Target_5_GenBank_ID_Protein:
Not Available

# Drug_Target_5_GeneCard_ID:
Not Available

# Drug_Target_5_Gene_Name:
cobU

# Drug_Target_5_Gene_Sequence:
>546 bp
TCATTTAATTTTGACTCCAATACCTGAGACTACCAGCCAGACCTCATCCGCCGCTGCCGC
CAGTCGTTGGTTGACCCGACCGGCAATATCACGAAAATGGCGCGCCAGACGGTTTTCCGG
GACGATCCCCATTCCCACCTCATTTGTCACCAGTACCACTTTCGCCGGGCAGCGCTGGCA
GGCTGCAATTAAAATCTGAATTTCATCGTCAATGGCGCGCTCCATCGCCGCGTAATCCCA
CTGTTCGGGATCGTTCTCGCCTCCCAGCGCAAACAGCAGATTCGTCACCATGGTGGTAAT
ACATTCCAGCAAAATCGCGTCGTCAGGGGCAAGATCCGCGGTAATCAACGTATCAAGATG
CCGCCAGCATTCTGCGGTCCGCCAGTGTGCCGGCCTGCCATCTTTATGATGCTGAATTCT
CGCCGCCATCTCGTCATCAAGAATCTGCGAGGTGGCGATATACAGTACCTGCGGCGCATC
GCCAATTAAGGCTTCAGCATGACGGCTTTTACCACTACGTGCCCCGCCCGTCACCAGAAT
CATCAT

# Drug_Target_5_General_Function:
Coenzyme transport and metabolism

# Drug_Target_5_General_References:
10529169	Thompson TB, Thomas MG, Escalante-Semerena JC, Rayment I: Three-dimensional structure of adenosylcobinamide kinase/adenosylcobinamide phosphate guanylyltransferase (CobU) complexed with GMP: evidence for a substrate-induced transferase active site. Biochemistry. 1999 Oct 5;38(40):12995-3005.
11677609	McClelland M, Sanderson KE, Spieth J, Clifton SW, Latreille P, Courtney L, Porwollik S, Ali J, Dante M, Du F, Hou S, Layman D, Leonard S, Nguyen C, Scott K, Holmes A, Grewal N, Mulvaney E, Ryan E, Sun H, Florea L, Miller W, Stoneking T, Nhan M, Waterston R, Wilson RK: Complete genome sequence of Salmonella enterica serovar Typhimurium LT2. Nature. 2001 Oct 25;413(6858):852-6.
8501034	Roth JR, Lawrence JG, Rubenfield M, Kieffer-Higgins S, Church GM: Characterization of the cobalamin (vitamin B12) biosynthetic genes of Salmonella typhimurium. J Bacteriol. 1993 Jun;175(11):3303-16.
9601028	Thompson TB, Thomas MG, Escalante-Semerena JC, Rayment I: Three-dimensional structure of adenosylcobinamide kinase/adenosylcobinamide phosphate guanylyltransferase from Salmonella typhimurium determined to 2.3 A resolution,. Biochemistry. 1998 May 26;37(21):7686-95.

# Drug_Target_5_HGNC_ID:
Not Available

# Drug_Target_5_HPRD_ID:
Not Available

# Drug_Target_5_ID:
4553

# Drug_Target_5_Locus:
Not Available

# Drug_Target_5_Molecular_Weight:
19902

# Drug_Target_5_Name:
Bifunctional adenosylcobalamin biosynthesis protein cobU

# Drug_Target_5_Number_of_Residues:
181

# Drug_Target_5_PDB_ID:
1C9K

# Drug_Target_5_Pathway:
Not Available

# Drug_Target_5_Pfam_Domain_Function:
PF02283	CobU

# Drug_Target_5_Protein_Sequence:
>Bifunctional adenosylcobalamin biosynthesis protein cobU
MMILVTGGARSGKSRHAEALIGDAPQVLYIATSQILDDEMAARIQHHKDGRPAHWRTAEC
WRHLDTLITADLAPDDAILLECITTMVTNLLFALGGENDPEQWDYAAMERAIDDEIQILI
AACQRCPAKVVLVTNEVGMGIVPENRLARHFRDIAGRVNQRLAAAADEVWLVVSGIGVKI
K

# Drug_Target_5_Reaction:
Not Available

# Drug_Target_5_Signals:
None

# Drug_Target_5_Specific_Function:
Catalyzes ATP-dependent phosphorylation of adenosylcobinamide and addition of GMP to adenosylcobinamide phosphate

# Drug_Target_5_SwissProt_ID:
Q05599

# Drug_Target_5_SwissProt_Name:
COBU_SALTY

# Drug_Target_5_Synonyms:
Not Available

# Drug_Target_5_Theoretical_pI:
5.26

# Drug_Target_5_Transmembrane_Regions:
None

# Drug_Target_6_Cellular_Location:
Not Available

# Drug_Target_6_Chromosome_Location:
Not Available

# Drug_Target_6_Drug_References:
Not Available

# Drug_Target_6_Essentiality:
Non-Essential

# Drug_Target_6_GenAtlas_ID:
Not Available

# Drug_Target_6_GenBank_ID_Gene:
M10101

# Drug_Target_6_GenBank_ID_Protein:
Not Available

# Drug_Target_6_GeneCard_ID:
Not Available

# Drug_Target_6_Gene_Name:
guaA

# Drug_Target_6_Gene_Sequence:
>1578 bp
ATGACGGAAAACATTCATAAGCATCGCATCCTCATTCTGGACTTCGGTTCTCAGTACACT
CAACTGGTTGCGCGCCGCGTGCGTGAGCTGGGTGTTTACTGCGAACTGTGGGCGTGGGAT
GTGACAGAAGCACAAATTCGTGACTTCAATCCAAGCGGCATTATTCTTTCCGGCGGCCCG
GAAAGTACTACTGAAGAAAACAGTCCGCGTGCGCCGCAGTATGTCTTTGAAGCAGGCGTA
CCGGTATTCGGCGTTTGCTATGGCATGCAGACCATGGCAATGCAGTTGGGCGGTCACGTT
GAAGCCTCTAACGAACGTGAATTTGGCTACGCGCAGGTTGAAGTCGTAAACGACAGCGCA
CTGGTTCGCGGTATCGAAGATGCGCTGACCGCAGACGGTAAACCGCTGCTCGATGTCTGG
ATGAGCCACGGCGATAAAGTTACCGCTATTCCGTCCGACTTCATCACCGTAGCCAGCACC
GAAAGCTGCCCGTTTGCCATTATGGCTAACGAAGAAAAACGCTTCTATGGCGTACAGTTC
CACCCGGAAGTGACTCATACCCGCCAGGGTATGCGCATGCTGGAGCGTTTTGTGCGTGAT
ATCTGCCAGTGTGAAGCCCTGTGGACGCCAGCGAAAATTATCGACGATGCTGTAGCTCGC
ATCCGCGAGCAGGTAGGCGACGATAAAGTCATCCTCGGCCTCTCTGGTGGTGTGGATTCC
TCCGTAACCGCAATGCTGCTGCACCGCGCTATCGGTAAAAACCTGACTTGCGTATTCGTC
GACAACGGCCTGCTGCGCCTCAACGAAGCAGAGCAGGTTCTGGATATGTTTGGCGATCAC
TTTGGTCTTAACATTGTTCACGTACCGGCAGAAGATCGCTTCCTGTCAGCGCTGGCTGGC
GAAAACGATCCGGAAGCAAAACGTAAAATCATCGGTCGCGTTTTCGTTGAAGTATTCGAT
GAAGAAGCGCTGAAACTGGAAGACGTGAAGTGGCTGGCGCAGGGCACCATCTACCCTGAC
GTTATCGAATCTGCGGCGTCTGCAACCGGTAAAGCACACGTCATCAAATCTCACCACAAC
GTGGGCGGCCTGCCGAAAGAGATGAAGATGGGCCTGGTTGAACCGCTGAAAGAGCTGTTC
AAAGACGAAGTGCGTAAGATTGGTCTGGAGCTGGGCCTGCCGTACGACATGCTGTACCGT
CACCCGTTCCCGGGACCAGGCCTTGGCGTTCGTGTTCTGGGTGAAGTGAAGAAAGAGTAC
TGTGACCTGCTGCGCCGTGCTGACGCCATCTTCATTGAAGAACTGCGTAAAGCGGACCTG
TACGACAAAGTCAGCCAGGCGTTCACTGTGTTCCTGCCGGTACGTTCCGTTGGCGTAATG
GGCGATGGTCGTAAGTATGACTGGGTTGTCTCTCTGCGTGCTGTCGAAACCATCGACTTT
ATGACCGCACACTGGGCGCATCTGCCGTACGATTTCCTCGGTCGCGTTTCCAACCGCATT
ATCAATGAAGTGAACGGTATTTCCCGCGTGGTGTATGACATCAGCGGCAAGCCGCCAGCT
ACCATTGAGTGGGAATGA

# Drug_Target_6_General_Function:
Involved in catalytic activity

# Drug_Target_6_General_References:
10856643	Hutchings MI, Drabble WT: Regulation of the divergent guaBA and xseA promoters of Escherichia coli by the cyclic AMP receptor protein. FEMS Microbiol Lett. 2000 Jun 15;187(2):115-22.
1736096	Tesfa-Selase F, Drabble WT: Regulation of the gua operon of Escherichia coli by the DnaA protein. Mol Gen Genet. 1992 Jan;231(2):256-64.
2982857	Zalkin H, Argos P, Narayana SV, Tiedeman AA, Smith JM: Identification of a trpG-related glutamine amide transfer domain in Escherichia coli GMP synthetase. J Biol Chem. 1985 Mar 25;260(6):3350-4.
3894345	Tiedeman AA, Smith JM, Zalkin H: Nucleotide sequence of the guaA gene encoding GMP synthetase of Escherichia coli K12. J Biol Chem. 1985 Jul 25;260(15):8676-9.
8548458	Tesmer JJ, Klem TJ, Deras ML, Davisson VJ, Smith JL: The crystal structure of GMP synthetase reveals a novel catalytic triad and is a structural paradigm for two enzyme families. Nat Struct Biol. 1996 Jan;3(1):74-86.
9205837	Yamamoto Y, Aiba H, Baba T, Hayashi K, Inada T, Isono K, Itoh T, Kimura S, Kitagawa M, Makino K, Miki T, Mitsuhashi N, Mizobuchi K, Mori H, Nakade S, Nakamura Y, Nashimoto H, Oshima T, Oyama S, Saito N, Sampei G, Satoh Y, Sivasundaram S, Tagami H, Horiuchi T, et al.: Construction of a contiguous 874-kb sequence of the Escherichia coli -K12 genome corresponding to 50.0-68.8 min on the linkage map and analysis of its sequence features. DNA Res. 1997 Apr 28;4(2):91-113.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.
9890911	Deras ML, Chittur SV, Davisson VJ: N2-hydroxyguanosine 5'-monophosphate is a time-dependent inhibitor of Escherichia coli guanosine monophosphate synthetase. Biochemistry. 1999 Jan 5;38(1):303-10.

# Drug_Target_6_HGNC_ID:
Not Available

# Drug_Target_6_HPRD_ID:
Not Available

# Drug_Target_6_ID:
4353

# Drug_Target_6_Locus:
Not Available

# Drug_Target_6_Molecular_Weight:
58680

# Drug_Target_6_Name:
GMP synthase [glutamine-hydrolyzing]

# Drug_Target_6_Number_of_Residues:
525

# Drug_Target_6_PDB_ID:
1GPM

# Drug_Target_6_Pathway:
Not Available

# Drug_Target_6_Pfam_Domain_Function:
PF00117	GATase
PF00958	GMP_synt_C
PF03054	tRNA_Me_trans

# Drug_Target_6_Protein_Sequence:
>GMP synthase [glutamine-hydrolyzing]
MTENIHKHRILILDFGSQYTQLVARRVRELGVYCELWAWDVTEAQIRDFNPSGIILSGGP
ESTTEENSPRAPQYVFEAGVPVFGVCYGMQTMAMQLGGHVEASNEREFGYAQVEVVNDSA
LVRGIEDALTADGKPLLDVWMSHGDKVTAIPSDFITVASTESCPFAIMANEEKRFYGVQF
HPEVTHTRQGMRMLERFVRDICQCEALWTPAKIIDDAVARIREQVGDDKVILGLSGGVDS
SVTAMLLHRAIGKNLTCVFVDNGLLRLNEAEQVLDMFGDHFGLNIVHVPAEDRFLSALAG
ENDPEAKRKIIGRVFVEVFDEEALKLEDVKWLAQGTIYPDVIESAASATGKAHVIKSHHN
VGGLPKEMKMGLVEPLKELFKDEVRKIGLELGLPYDMLYRHPFPGPGLGVRVLGEVKKEY
CDLLRRADAIFIEELRKADLYDKVSQAFTVFLPVRSVGVMGDGRKYDWVVSLRAVETIDF
MTAHWAHLPYDFLGRVSNRIINEVNGISRVVYDISGKPPATIEWE

# Drug_Target_6_Reaction:
Not Available

# Drug_Target_6_Signals:
None

# Drug_Target_6_Specific_Function:
Catalyzes the synthesis of GMP from XMP

# Drug_Target_6_SwissProt_ID:
P04079

# Drug_Target_6_SwissProt_Name:
GUAA_ECOLI

# Drug_Target_6_Synonyms:
EC 6.3.5.2
GMP synthetase
GMPS
Glutamine amidotransferase

# Drug_Target_6_Theoretical_pI:
5.06

# Drug_Target_6_Transmembrane_Regions:
None

# Drug_Target_7_Cellular_Location:
Cytoplasm

# Drug_Target_7_Chromosome_Location:
Not Available

# Drug_Target_7_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_7_Essentiality:
Non-Essential

# Drug_Target_7_GenAtlas_ID:
HPRT1

# Drug_Target_7_GenBank_ID_Gene:
M31642

# Drug_Target_7_GenBank_ID_Protein:
306885

# Drug_Target_7_GeneCard_ID:
HPRT1

# Drug_Target_7_Gene_Name:
HPRT1

# Drug_Target_7_Gene_Sequence:
>657 bp
ATGGCGACCCGCAGCCCTGGCGTCGTGATTAGTGATGATGAACCAGGTTATGACCTTGAT
TTATTTTGCATACCTAATCATTATGCTGAGGATTTGGAAAGGGTGTTTATTCCTCATGGA
CTAATTATGGACAGGACTGAACGTCTTGCTCGAGATGTGATGAAGGAGATGGGAGGCCAT
CACATTGTAGCCCTCTGTGTGCTCAAGGGGGGCTATAAATTCTTTGCTGACCTGCTGGAT
TACATCAAAGCACTGAATAGAAATAGTGATAGATCCATTCCTATGACTGTAGATTTTATC
AGACTGAAGAGCTATTGTAATGACCAGTCAACAGGGGACATAAAAGTAATTGGTGGAGAT
GATCTCTCAACTTTAACTGGAAAGAATGTCTTGATTGTGGAAGATATAATTGACACTGGC
AAAACAATGCAGACTTTGCTTTCCTTGGTCAGGCAGTATAATCCAAAGATGGTCAAGGTC
GCAAGCTTGCTGGTGAAAAGGACCCCACGAAGTGTTGGATATAAGCCAGACTTTGTTGGA
TTTGAAATTCCAGACAAGTTTGTTGTAGGATATGCCCTTGACTATAATGAATACTTCAGG
GATTTGAATCATGTTTGTGTCATTAGTGAAACTGGAAAAGCAAAATACAAAGCCTAA

# Drug_Target_7_General_Function:
Nucleotide transport and metabolism

# Drug_Target_7_General_References:
10338013	Balendiran GK, Molina JA, Xu Y, Torres-Martinez J, Stevens R, Focia PJ, Eakin AE, Sacchettini JC, Craig SP 3rd: Ternary complex structure of human HGPRTase, PRPP, Mg2+, and the inhibitor HPP reveals the involvement of the flexible loop in substrate binding. Protein Sci. 1999 May;8(5):1023-31.
10360366	Shi W, Li CM, Tyler PC, Furneaux RH, Grubmeyer C, Schramm VL, Almo SC: The 2.0 A structure of human hypoxanthine-guanine phosphoribosyltransferase in complex with a transition-state analog inhibitor. Nat Struct Biol. 1999 Jun;6(6):588-93.
1301916	Sege-Peterson K, Chambers J, Page T, Jones OW, Nyhan WL: Characterization of mutations in phenotypic variants of hypoxanthine phosphoribosyltransferase deficiency. Hum Mol Genet. 1992 Sep;1(6):427-32.
1487231	Sculley DG, Dawson PA, Emmerson BT, Gordon RB: A review of the molecular basis of hypoxanthine-guanine phosphoribosyltransferase (HPRT) deficiency. Hum Genet. 1992 Nov;90(3):195-207.
1551676	Lightfoot T, Joshi R, Nuki G, Snyder FF: The point mutation of hypoxanthine-guanine phosphoribosyltransferase (HPRTEdinburgh) and detection by allele-specific polymerase chain reaction. Hum Genet. 1992 Mar;88(6):695-6.
1840476	Yamada Y, Goto H, Ogasawara N: Identification of two independent Japanese mutant HPRT genes using the PCR technique. Adv Exp Med Biol. 1991;309B:121-4.
1937471	Sculley DG, Dawson PA, Beacham IR, Emmerson BT, Gordon RB: Hypoxanthine-guanine phosphoribosyltransferase deficiency: analysis of HPRT mutations by direct sequencing and allele-specific amplification. Hum Genet. 1991 Oct;87(6):688-92.
2018042	Davidson BL, Tarle SA, Van Antwerp M, Gibbs DA, Watts RW, Kelley WN, Palella TD: Identification of 17 independent mutations responsible for human hypoxanthine-guanine phosphoribosyltransferase (HPRT) deficiency. Am J Hum Genet. 1991 May;48(5):951-8.
2071157	Tarle SA, Davidson BL, Wu VC, Zidar FJ, Seegmiller JE, Kelley WN, Palella TD: Determination of the mutations responsible for the Lesch-Nyhan syndrome in 17 subjects. Genomics. 1991 Jun;10(2):499-501.
2246854	Gordon RB, Sculley DG, Dawson PA, Beacham IR, Emmerson BT: Identification of a single nucleotide substitution in the coding sequence of in vitro amplified cDNA from a patient with partial HPRT deficiency (HPRTBRISBANE). J Inherit Metab Dis. 1990;13(5):692-700.
2341149	Edwards A, Voss H, Rice P, Civitello A, Stegemann J, Schwager C, Zimmermann J, Erfle H, Caskey CT, Ansorge W: Automated DNA sequencing of the human HPRT locus. Genomics. 1990 Apr;6(4):593-608.
2347587	Gibbs RA, Nguyen PN, Edwards A, Civitello AB, Caskey CT: Multiplex DNA deletion detection and exon sequencing of the hypoxanthine phosphoribosyltransferase gene in Lesch-Nyhan families. Genomics. 1990 Jun;7(2):235-44.
2358296	Skopek TR, Recio L, Simpson D, Dallaire L, Melancon SB, Ogier H, O'Neill JP, Falta MT, Nicklas JA, Albertini RJ: Molecular analyses of a Lesch-Nyhan syndrome mutation (hprtMontreal) by use of T-lymphocyte cultures. Hum Genet. 1990 Jun;85(1):111-6.
2572141	Igarashi T, Minami M, Nishida Y: Molecular analysis of hypoxanthine-guanine phosphoribosyltransferase mutations in five unrelated Japanese patients. Acta Paediatr Jpn. 1989 Jun;31(3):303-13.
2738157	Davidson BL, Tarle SA, Palella TD, Kelley WN: Molecular basis of hypoxanthine-guanine phosphoribosyltransferase deficiency in ten subjects determined by direct sequencing of amplified transcripts. J Clin Invest. 1989 Jul;84(1):342-6.
2896620	Fujimori S, Hidaka Y, Davidson BL, Palella TD, Kelley WN: Identification of a single nucleotide change in a mutant gene for hypoxanthine-guanine phosphoribosyltransferase (HPRT Ann Arbor). Hum Genet. 1988 May;79(1):39-43.
2909537	Davidson BL, Pashmforoush M, Kelley WN, Palella TD: Human hypoxanthine-guanine phosphoribosyltransferase deficiency. The molecular defect in a patient with gout (HPRTAshville). J Biol Chem. 1989 Jan 5;264(1):520-5.
2910902	Fujimori S, Davidson BL, Kelley WN, Palella TD: Identification of a single nucleotide change in the hypoxanthine-guanine phosphoribosyltransferase gene (HPRTYale) responsible for Lesch-Nyhan syndrome. J Clin Invest. 1989 Jan;83(1):11-3.
2928313	Gibbs RA, Nguyen PN, McBride LJ, Koepf SM, Caskey CT: Identification of mutations leading to the Lesch-Nyhan syndrome by automated direct DNA sequencing of in vitro amplified cDNA. Proc Natl Acad Sci U S A. 1989 Mar;86(6):1919-23.
3023844	Patel PI, Framson PE, Caskey CT, Chinault AC: Fine structure of the human hypoxanthine phosphoribosyltransferase gene. Mol Cell Biol. 1986 Feb;6(2):393-403.
3148064	Keough DT, Gordon RB, de Jersey J, Emmerson BT: Biochemical basis of hypoxanthine-guanine phosphoribosyltransferase deficiency in nine families. J Inherit Metab Dis. 1988;11(3):229-38.
3198771	Davidson BL, Chin SJ, Wilson JM, Kelley WN, Palella TD: Hypoxanthine-guanine phosphoribosyltransferase. Genetic evidence for identical mutations in two partially deficient subjects. J Clin Invest. 1988 Dec;82(6):2164-7.
3265398	Davidson BL, Palella TD, Kelley WN: Human hypoxanthine-guanine phosphoribosyltransferase: a single nucleotide substitution in cDNA clones isolated from a patient with Lesch-Nyhan syndrome (HPRTMidland). Gene. 1988 Aug 15;68(1):85-91.
3358423	Cariello NF, Scott JK, Kat AG, Thilly WG, Keohavong P: Resolution of a missense mutant in human genomic DNA by denaturing gradient gel electrophoresis and direct sequencing using in vitro DNA amplification: HPRT Munich. Am J Hum Genet. 1988 May;42(5):726-34.
3384338	Davidson BL, Pashmforoush M, Kelley WN, Palella TD: Genetic basis of hypoxanthine guanine phosphoribosyltransferase deficiency in a patient with the Lesch-Nyhan syndrome (HPRTFlint). Gene. 1988 Mar 31;63(2):331-6.
6300847	Jolly DJ, Okayama H, Berg P, Esty AC, Filpula D, Bohlen P, Johnson GG, Shively JE, Hunkapillar T, Friedmann T: Isolation and characterization of a full-length expressible cDNA for human hypoxanthine phosphoribosyl transferase. Proc Natl Acad Sci U S A. 1983 Jan;80(2):477-81.
6572373	Wilson JM, Tarr GE, Kelley WN: Human hypoxanthine (guanine) phosphoribosyltransferase: an amino acid substitution in a mutant form of the enzyme isolated from a patient with gout. Proc Natl Acad Sci U S A. 1983 Feb;80(3):870-3.
6706936	Wilson JM, Kelley WN: Human hypoxanthine-guanine phosphoribosyltransferase. Structural alteration in a dysfunctional enzyme variant (HPRTMunich) isolated from a patient with gout. J Biol Chem. 1984 Jan 10;259(1):27-30.
6853490	Wilson JM, Kobayashi R, Fox IH, Kelley WN: Human hypoxanthine-guanine phosphoribosyltransferase. J Biol Chem. 1983 May 25;258(10):6458-60.
6853716	Wilson JM, Kelley WN: Molecular basis of hypoxanthine-guanine phosphoribosyltransferase deficiency in a patient with the Lesch-Nyhan syndrome. J Clin Invest. 1983 May;71(5):1331-5.
7107641	Wilson JM, Tarr GE, Mahoney WC, Kelley WN: Human hypoxanthine-guanine phosphoribosyltransferase. Complete amino acid sequence of the erythrocyte enzyme. J Biol Chem. 1982 Sep 25;257(18):10978-85.
7627191	Burgemeister R, Rotzer E, Gutensohn W, Gehrke M, Schiel W: Identification of a new missense mutation in exon 2 of the human hypoxanthine phosphoribosyltransferase gene (HPRTIsar): a further example of clinical heterogeneity in HPRT deficiencies. Hum Mutat. 1995;5(4):341-4.
8044844	Eads JC, Scapin G, Xu Y, Grubmeyer C, Sacchettini JC: The crystal structure of human hypoxanthine-guanine phosphoribosyltransferase with bound GMP. Cell. 1994 Jul 29;78(2):325-34.
9003484	Fujimori S, Sakuma R, Yamaoka N, Hakoda M, Yamanaka H, Kamatani N: An asymptomatic germline missense base substitution in the hypoxanthine phosphoribosyltransferase (HPRT) gene that reduces the amount of enzyme in humans. Hum Genet. 1997 Jan;99(1):8-10.
9452051	Liu G, Aral B, Zabot MT, Kamoun P, Ceballos-Picot I: The molecular basis of hypoxanthine-guanine phosphoribosyltransferase deficiency in French families; report of two novel mutations. Hum Mutat. 1998;Suppl 1:S88-90.

# Drug_Target_7_HGNC_ID:
HGNC:5157

# Drug_Target_7_HPRD_ID:
02388

# Drug_Target_7_ID:
87

# Drug_Target_7_Locus:
Xq26.1

# Drug_Target_7_Molecular_Weight:
24448

# Drug_Target_7_Name:
Hypoxanthine-guanine phosphoribosyltransferase

# Drug_Target_7_Number_of_Residues:
217

# Drug_Target_7_PDB_ID:
1BZY

# Drug_Target_7_Pathway:
Azathioprine Pathway	SMP00427
Mercaptopurine Pathway	SMP00428
Thioguanine Pathway	SMP00430

# Drug_Target_7_Pfam_Domain_Function:
PF00156	Pribosyltran

# Drug_Target_7_Protein_Sequence:
>Hypoxanthine-guanine phosphoribosyltransferase
ATRSPGVVISDDEPGYDLDLFCIPNHYAEDLERVFIPHGLIMDRTERLARDVMKEMGGHH
IVALCVLKGGYKFFADLLDYIKALNRNSDRSIPMTVDFIRLKSYCNDQSTGDIKVIGGDD
LSTLTGKNVLIVEDIIDTGKTMQTLLSLVRQYNPKMVKVASLLVKRTPRSVGYKPDFVGF
EIPDKFVVGYALDYNEYFRDLNHVCVISETGKAKYKA

# Drug_Target_7_Reaction:
IMP + diphosphate = hypoxanthine + 5-phospho-alpha-D-ribose 1-diphosphate

# Drug_Target_7_Signals:
None

# Drug_Target_7_Specific_Function:
Not Available

# Drug_Target_7_SwissProt_ID:
P00492

# Drug_Target_7_SwissProt_Name:
HPRT_HUMAN

# Drug_Target_7_Synonyms:
EC 2.4.2.8
HGPRT
HGPRTase

# Drug_Target_7_Theoretical_pI:
6.67

# Drug_Target_7_Transmembrane_Regions:
None

# Drug_Target_8_Cellular_Location:
Cell membrane
multi-pass membrane protein (Probable)

# Drug_Target_8_Chromosome_Location:
Not Available

# Drug_Target_8_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_8_Essentiality:
Non-Essential

# Drug_Target_8_GenAtlas_ID:
Not Available

# Drug_Target_8_GenBank_ID_Gene:
X52734

# Drug_Target_8_GenBank_ID_Protein:
46758

# Drug_Target_8_GeneCard_ID:
Not Available

# Drug_Target_8_Gene_Name:
blaR1

# Drug_Target_8_Gene_Sequence:
>1758 bp
TTATTGGCCATTTAAAACACCCATTTCTTTTAATATTTTTTCACTGATTAATTCAGCATT
TTTCCCAGATGGCTTTCCATCTGATAAATGTGTAGCAAAATAATACTTATCATGATTTGT
AATTACGTAACCTACAAACCACCCATTATTATACTTCCCGTTTACTATACCTGTACCTGT
TTTCCCATACAGTTCATACTTTTCATTTTTCTTAATCAATAATGAAGAAGATAATTGATT
CTTTGCTTTTTTACTAAAATGGTTATTTTGTTCCATCATATTTTTAAAAACTATTACTTG
TTCAAGATTAGATATTTTCAAACTATCTTCCATCCAATAGCTTTTATAACTTCCCAAATT
TTTATTACCATAATTTAATTGCTTGAGTTGAGTCGCAGTATAGTTCTTTGGTATTTGATC
GCTAATACGTTCGAAGTACCAATTAACTGAATTTTGCATTGCTGTATTTAAATCTTGTTC
CTTATTCCAAGCATCAAAAGGGTAATGCTTATGATTCCATGACATACGTGAATTTTCATC
ATTTATAATATGTCGGTCAAGTCCAAACATAGCTAAATAAATTTTATAAGTTGAATTAGG
AGAATACCTTTTTCTACTTTCTTTTTCGTTATAAATATAGTATTTGTCTTTCTTCATGCT
GTACATGACGAAAGATCCACTATTTGAACCAAAAATTTTACTTTTATCTAAAATTTGGTA
ATCGTTGTGTAAGGGCTTTTTATAATTATAATCAGTTATGGATTGCCCCATCAAAAACTG
GCTTTGAATTACCATGAGCAAAAAAGTAAAAATACAAATAAAAATTAGAATTAATTTGGA
CTGTTTTTTCAGATTGGCTTCTTTTATATTAATTAATCTTCTTTTGAGTAATGACTTTTT
ACCATTAAATGAATGGCTTAATATATTTTTATTAAAAAATGGAACATTTAATACGGAGTC
CATAATAGATTCCGCATAAGTTTTAAATTCATTTTTGTTAATATTATTAAGGACAAATCT
ATCGGCTTCTACTTCATTGTCATGAATTATCTTTCTTTTTACAATATGTACTAATGGATT
GTAACTCATAATAATAGAGAAGATATTAAAGATAATTAAATGTAAAGTATCTCTATTTTT
AGCATGAGCATATTCATGCAATATTATATATTTTAGTCTTTTGTCAATTACACTTTTAAA
ATATGAACTAGGAATCAAAATAATATATTTCCCATACCAAAAAGTTATTGGAGATTGAAT
AGTCTCTGCTTTTCGAATCACAATATTTTTTTTATATTGATGGTTGAAAAGTATCGTATC
TATTTTATTTTTTTCATTTTCGTTTAGATAAAGTGACTGTTTCTTTAAATATTTAAGATA
TAATAAGGCTTTCAAAAATTTAAAACTTAAAATAATAACTAAAACTATCCAAATAACTGT
GCTGATATTATCAATTGAATCCCAATTAAACTTATGGATATCTGTTGCGAACTCTTGAAT
AGGTTTGGTGGTATTTATGTTATGGTTCAAGTCGTGTGACTTACTTTCAACTGTGGGCGC
TTGATTATTCACATTATTAAATTTAAAAAGAGAGAATTTAATAGGAATGAAAGGAATTAA
TCCTGCAAGAAGAGTTAGATACCAAACTTTATAATTTAACATATAATTAAAATAGCGTTT
TAATATGTACCTAAAAAATAATAACAATAGAAATATAAAACAAAAGCTTACTATGCTCAT
TATTAATAACTTAGCCAT

# Drug_Target_8_General_Function:
Defense mechanisms and antibiotic binding

# Drug_Target_8_General_References:
2170815	Rowland SJ, Dyke KG: Tn552, a novel transposable element from Staphylococcus aureus. Mol Microbiol. 1990 Jun;4(6):961-75.

# Drug_Target_8_HGNC_ID:
Not Available

# Drug_Target_8_HPRD_ID:
Not Available

# Drug_Target_8_ID:
3010

# Drug_Target_8_Locus:
Not Available

# Drug_Target_8_Molecular_Weight:
69246

# Drug_Target_8_Name:
Regulatory protein blaR1

# Drug_Target_8_Number_of_Residues:
585

# Drug_Target_8_PDB_ID:
1XA1

# Drug_Target_8_Pathway:
Not Available

# Drug_Target_8_Pfam_Domain_Function:
PF00905	Transpeptidase
PF05569	Peptidase_M56

# Drug_Target_8_Protein_Sequence:
>Regulatory protein blaR1
MAKLLIMSIVSFCFIFLLLLFFRYILKRYFNYMLNYKVWYLTLLAGLIPFIPIKFSLFKF
NNVNNQAPTVESKSHDLNHNINTTKPIQEFATDIHKFNWDSIDNISTVIWIVLVIILSFK
FLKALLYLKYLKKQSLYLNENEKNKIDTILFNHQYKKNIVIRKAETIQSPITFWYGKYII
LIPSSYFKSVIDKRLKYIILHEYAHAKNRDTLHLIIFNIFSIIMSYNPLVHIVKRKIIHD
NEVEADRFVLNNINKNEFKTYAESIMDSVLNVPFFNKNILSHSFNGKKSLLKRRLINIKE
ANLKKQSKLILIFICIFTFLLMVIQSQFLMGQSITDYNYKKPLHNDYQILDKSKIFGSNS
GSFVMYSMKKDKYYIYNEKESRKRYSPNSTYKIYLAMFGLDRHIINDENSRMSWNHKHYP
FDAWNKEQDLNTAMQNSVNWYFERISDQIPKNYTATQLKQLNYGNKNLGSYKSYWMEDSL
KISNLEQVIVFKNMMEQNNHFSKKAKNQLSSSLLIKKNEKYELYGKTGTGIVNGKYNNGW
FVGYVITNHDKYYFATHLSDGKPSGKNAELISEKILKEMGVLNGQ

# Drug_Target_8_Reaction:
Not Available

# Drug_Target_8_Signals:
None

# Drug_Target_8_Specific_Function:
BlaR1 is a potential penicillin-binding protein required for induction of beta-lactamase

# Drug_Target_8_SwissProt_ID:
P18357

# Drug_Target_8_SwissProt_Name:
BLAR_STAAU

# Drug_Target_8_Synonyms:
Not Available

# Drug_Target_8_Theoretical_pI:
10.12

# Drug_Target_8_Transmembrane_Regions:
4-22
38-58
108-128
214-233
309-330

# Drug_Target_9_Cellular_Location:
Not Available

# Drug_Target_9_Chromosome_Location:
Not Available

# Drug_Target_9_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_9_Essentiality:
Non-Essential

# Drug_Target_9_GenAtlas_ID:
Not Available

# Drug_Target_9_GenBank_ID_Gene:
M15811

# Drug_Target_9_GenBank_ID_Protein:
143279

# Drug_Target_9_GeneCard_ID:
Not Available

# Drug_Target_9_Gene_Name:
nadE

# Drug_Target_9_Gene_Sequence:
>819 bp
ATGAGCATGCAGGAAAAGATTATGCGTGAGTTACATGTGAAGCCCTCAATTGATCCAAAG
CAAGAAATTGAGGACCGAGTCAATTTTTTAAAACAATATGTAAAGAAAACCGGTGCTAAA
GGCTTTGTATTGGGAATCAGCGGGGGCCAGGATTCAACACTTGCGGGAAGACTCGCTCAG
CTTGCGGTGGAGAGCATTCGCGAGGAGGGCGGAGACGCTCAATTTATCGCGGTCCGTCTT
CCGCATGGCACACAGCAGGATGAAGACGATGCCCAGCTTGCTTTGAAGTTTATTAAGCCG
GATAAATCATGGAAGTTTGATATTAAATCGACAGTCAGCGCTTTTTCTGATCAGTATCAG
CAGGAAACAGGCGATCAGCTGACGGACTTTAATAAAGGAAACGTAAAAGCAAGAACAAGA
ATGATCGCGCAATACGCGATCGGCGGCCAGGAAGGTCTTCTTGTGTTAGGAACAGACCAT
GCTGCTGAAGCAGTGACTGGTTTCTTTACGAAGTACGGTGACGGCGGAGCAGACCTCCTG
CCGCTGACAGGCTTGACGAAGCGCCAGGGAAGAACCTTGCTGAAAGAGCTGGGTGCACCG
GAACGCTTATACTTAAAAGAACCGACTGCCGATCTGCTCGACGAAAAACCGCAGCAGTCG
GATGAAACAGAGCTTGGCATTTCCTACGACGAGATTGACGATTATCTCGAAGGAAAAGAA
GTATCAGCGAAAGTATCAGAAGCGCTGGAAAAACGCTACAGCATGACTGAACATAAACGC
CAGGTTCCGGCGTCTATGTTTGATGACTGGTGGAAATAA

# Drug_Target_9_General_Function:
Coenzyme transport and metabolism

# Drug_Target_9_General_References:
11375500	Devedjiev Y, Symersky J, Singh R, Jedrzejas M, Brouillette C, Brouillette W, Muccio D, Chattopadhyay D, DeLucas L: Stabilization of active-site loops in NH3-dependent NAD+ synthetase from Bacillus subtilis. Acta Crystallogr D Biol Crystallogr. 2001 Jun;57(Pt 6):806-12. Epub 2001 May 25.
12077433	Symersky J, Devedjiev Y, Moore K, Brouillette C, DeLucas L: NH3-dependent NAD+ synthetase from Bacillus subtilis at 1 A resolution. Acta Crystallogr D Biol Crystallogr. 2002 Jul;58(Pt 7):1138-46. Epub 2002 Jun 20.
1556067	Mitchell C, Morris PW, Vary JC: Identification of proteins phosphorylated by ATP during sporulation of Bacillus subtilis. J Bacteriol. 1992 Apr;174(8):2474-7.
2118513	Albertini AM, Galizzi A: The Bacillus subtilis outB gene is highly homologous to an Escherichia coli ntr-like gene. J Bacteriol. 1990 Sep;172(9):5482-5.
2435704	Albertini AM, Caramori T, Henner D, Ferrari E, Galizzi A: Nucleotide sequence of the outB locus of Bacillus subtilis and regulation of its expression. J Bacteriol. 1987 Apr;169(4):1480-4.
7890752	Nessi C, Albertini AM, Speranza ML, Galizzi A: The outB gene of Bacillus subtilis codes for NAD synthetase. J Biol Chem. 1995 Mar 17;270(11):6181-5.
8895556	Rizzi M, Nessi C, Mattevi A, Coda A, Bolognesi M, Galizzi A: Crystal structure of NH3-dependent NAD+ synthetase from Bacillus subtilis. EMBO J. 1996 Oct 1;15(19):5125-34.
8969502	Yamane K, Kumano M, Kurita K: The 25 degrees-36 degrees region of the Bacillus subtilis chromosome: determination of the sequence of a 146 kb segment and identification of 113 genes. Microbiology. 1996 Nov;142 ( Pt 11):3047-56.
9298659	Antelmann H, Bernhardt J, Schmid R, Mach H, Volker U, Hecker M: First steps from a two-dimensional protein index towards a response-regulation map for Bacillus subtilis. Electrophoresis. 1997 Aug;18(8):1451-63.
9384377	Kunst F, Ogasawara N, Moszer I, Albertini AM, Alloni G, Azevedo V, Bertero MG, Bessieres P, Bolotin A, Borchert S, Borriss R, Boursier L, Brans A, Braun M, Brignell SC, Bron S, Brouillet S, Bruschi CV, Caldwell B, Capuano V, Carter NM, Choi SK, Codani JJ, Connerton IF, Danchin A, et al.: The complete genome sequence of the gram-positive bacterium Bacillus subtilis. Nature. 1997 Nov 20;390(6657):249-56.
9753692	Rizzi M, Bolognesi M, Coda A: A novel deamido-NAD+-binding site revealed by the trapped NAD-adenylate intermediate in the NAD+ synthetase structure. Structure. 1998 Sep 15;6(9):1129-40.

# Drug_Target_9_HGNC_ID:
Not Available

# Drug_Target_9_HPRD_ID:
Not Available

# Drug_Target_9_ID:
2910

# Drug_Target_9_Locus:
Not Available

# Drug_Target_9_Molecular_Weight:
30396

# Drug_Target_9_Name:
NH(3)-dependent NAD(+) synthetase

# Drug_Target_9_Number_of_Residues:
272

# Drug_Target_9_PDB_ID:
1IH8

# Drug_Target_9_Pathway:
Not Available

# Drug_Target_9_Pfam_Domain_Function:
PF02540	NAD_synthase

# Drug_Target_9_Protein_Sequence:
>NH(3)-dependent NAD(+) synthetase
MSMQEKIMRELHVKPSIDPKQEIEDRVNFLKQYVKKTGAKGFVLGISGGQDSTLAGRLAQ
LAVESIREEGGDAQFIAVRLPHGTQQDEDDAQLALKFIKPDKSWKFDIKSTVSAFSDQYQ
QETGDQLTDFNKGNVKARTRMIAQYAIGGQEGLLVLGTDHAAEAVTGFFTKYGDGGADLL
PLTGLTKRQGRTLLKELGAPERLYLKEPTADLLDEKPQQSDETELGISYDEIDDYLEGKE
VSAKVSEALEKRYSMTEHKRQVPASMFDDWWK

# Drug_Target_9_Reaction:
ATP + deamido-NAD+ + NH3 = AMP + diphosphate + NAD+

# Drug_Target_9_Signals:
None

# Drug_Target_9_Specific_Function:
Catalyzes a key step in NAD biosynthesis, transforming deamido-NAD into NAD by a two-step reaction

# Drug_Target_9_SwissProt_ID:
P08164

# Drug_Target_9_SwissProt_Name:
NADE_BACSU

# Drug_Target_9_Synonyms:
EC 6.3.1.5
GSP38
General stress protein 38
Spore outgrowth factor B
Sporulation protein outB

# Drug_Target_9_Theoretical_pI:
4.83

# Drug_Target_9_Transmembrane_Regions:
None

#END_DRUGCARD DB02212
